Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically ~~and posted on its corporate Web site, if any,~~ every Interactive Data File required to be submitted ~~and posted~~ pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit ~~and post~~ such files). Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes [ ] No [X]

~~APPLICABLE ONLY TO REGISTRANTS INVOLVED IN BANKRUPTCY~~
~~PROCEEDINGS DURING THE PRECEDING FIVE YEARS:~~

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Section S 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes [ ] No [X]

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date. As of ~~April 16, 2018,~~January 14, 2019, there were 30,799,046 Class A shares of common stock, par value $0.001; 6,000,000 Class B shares of common stock, par value $0.001, and ~~73,400,000~~73,550,000 Class C shares of common stock, par value $0.001 of the registrant issued and outstanding.

The accompanying notes are an integral part of these consolidated financial statements.

The Company was organized August 26, 2010 (Date of Inception) under the laws of the State of Nevada, as JA Energy. The Company was incorporated as a subsidiary of Reshoot Production Company, a Nevada corporation. Reshoot Production Company was incorporated October 31, 2007. In November 2014, Reshoot dividended its shares of JA Energy to the then stockholders of Reshoot. On November 21, 2016, the Company reincorporated in Delaware under the name UBI Blockchain Internet Ltd.

On September 15, 2016, the Company, with the approval of the Board of Directors agreed to issue 30,000,000 shares of unregistered restricted Class A Common Stock, 6,000,000 shares of unregistered restricted Class B Voting Common Stock, which carries a voting weight equal to ten (10) Common Shares, and 40,000,000 shares of unregistered restricted Class C Common Stock to UBI Blockchain Internet, LTD (“UBI Hong Kong”), a Hong Kong company, or assigns in exchange for $200,000. On September 26, 2016, pursuant to NRS 78.1955, the Board of Directors approved the filing of a Certificate of Designation with the Nevada Secretary of State to designate Class A, B and C common shares, par value $0.001. Concurrently with the filing of this Certificate of Designation, all Common Stock issued and outstanding became Class A Common Stock. Class B Common Stock carries a voting weight equal to ten (10) Common Shares. The Class B shares can be converted into fully paid and non-assessable Common Shares, on a one-to-one basis, at the option of the holder at any time upon written notice to the Company and its authorized transfer agent. Class C Common Stock has no voting ~~rights. Upon the~~or conversion or other exchange of all outstanding shares of Class B Common Stock into or for shares of Class A Common Stock, all shares of Class C Common Stock shall be automatically, without further action by any holder thereof, converted into an identical number of fully paid and non-assessable shares of Class A Common Stock on the date fixed therefore by the Board of Directors that is no less than sixty-one days and no more than one hundred and eighty days following such conversion or exchange.rights.

On October 7, 2016, the 30,000,000 Class A shares and 6,000,000 Class B shares were issued.

On November 21, 2016, the Company reincorporated in Delaware under the name UBI Blockchain Internet Ltd. and increased the number of authorized shares from 75,000,000 to 200,000,000 shares consisting of 130,000,000 authorized shares of Class A Common Stock, 6,000,000 authorized shares of Class B Common Stock and 64,000,000 authorized shares of Class C Common Stock. On March 1, 2017, the 40,000,000 shares of Class C common stock were issued. All of the preceding shares were issued in reliance on the exemption under Section 4(2) of the Securities Act of 1933, as amended (the “Act”) and were issued under Regulation S to one (1) foreign entity who attested it is an accredited investor who is not a citizen or a resident of the USA.

On January 3, 2017, the Company appointed four new directors, accepted the resignations of its two former directors and appointed Tony Liu (who controls UBI Hong Kong) as Chief Executive Officer of the Company.

Commencing in the three months ended February 28, 2017, the Company started research activities in Hong Kong relating to “blockchain” technology planned to be provided for future customers.

On March 1, 2017, the Company issued 40,000,000 shares of Class C common stock to our chief executive officer Tony Liu pursuant to the September 15, 2016 agreement (see above).

On April 3, 2017, the Company issued a total of 8.400,000 shares of Class C common stock to a total of 45 contractor employees and nonemployees (see Note 6)7).

On May 1, 2017, the Company issued 500,000 restricted shares of Class A common stock to an independent consultant for consulting services to be performed for the Company (see Note 6)7).

On May 24, 2017, the Company increased the number of authorized common shares from 200,000,000 shares to 2,000,000,000 shares (1,000,000,000 shares of Class A common stock, 500,000,000 shares of Class B common stock, and 500,000,000 shares of Class C common stock).

On August 29, 2017, upon the approval of the acquisition by the related PRC authorities, the Company issued a total of 25,000,000 shares of Class C common stock to shareholders of Shenzhen Nova E-commerce, Ltd. (“Nova”) in exchange for control of the business of Nova (see Notes 4 and 6)7). On April 7, 2018, Nova changed its name to UBI Shenzhen Cross Border E- Commerce Co., Ltd. (“UBI Shenzhen”).

UBI Blockchain Internet Ltd. (“UBI Delaware”) was reincorporated in Delaware on November 21, 2016 for the purpose of entering into the blockchain technology business. UBI Blockchain Internet, Ltd (“UBI Hong Kong”) was organized in the Hong Kong Special Administrative Region (the “HKSAR”) in September 2016 to facilitate local financing ~~participations,~~participations. UBI Delaware ~~uses~~opened a bank ~~accounts~~account at Abacus Federal Savings Bank in New York City. This bank account is funded by Tony Liu and is used to pay Company invoices from the ~~name of~~U.S. UBI Hong Kong ~~to collect cash receipts and expend cash~~has a bank account at China Citic Bank International in Hong Kong, which is also funded by Tony Liu; this account makes disbursements relating to UBI Delaware operations in Hong Kong (such as payroll, rent, and other office expenses). UBI Hong Kong is owned and controlled by Tony Liu, CEO of UBI Delaware. UBI Hong Kong owns 30,000,000 (97%) of the 30,799,046 issued and outstanding shares of UBI Delaware Class A common stock at ~~February 28,~~November 30, 2018. UBI Hong Kong has no other assets and no business operations of its own.

In December 2016, UBI Delaware engaged the services of 8 full time employees to principally work in its blockchain technology business. In January 2018, UBI Hong Kong executed an agreement with the HKSAR and The Hong Kong Polytechnic University to complete a project related to blockchain technology (see Note ~~11)~~12). ~~To date,~~Through August 31, 2018, UBI Delaware, ~~has~~UBI Hong Kong, and UBI Shenzhen did not ~~received~~receive or ~~earned~~earn any revenues in its blockchain technology business.

The accompanying condensed unaudited financial statements have been prepared in accordance with generally accepted accounting principles applicable to a going concern which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. At ~~February 28,~~November 30, 2018, the Company had cash of ~~$59,523~~$189,323 and current liabilities of ~~$1,337,836.~~$2,525,753. For the ~~six~~three months ended ~~February 28,~~November 30, 2018, the Company incurred a net loss of ~~$1,907,501.~~$476,458. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.

The accompanying condensed unaudited financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from the outcome of this uncertainty.

The consolidated balance sheet ~~for~~of the Company at the end of the preceding fiscal year has been derived from the audited balance sheet and notes thereto contained in the Company’s annual report on Form 10-K for the fiscal year ended August 31, ~~2017~~2018 and is presented herein for comparative purposes. All other financial statements are unaudited. In the opinion of management, all adjustments, which include only normal recurring adjustments necessary to present fairly the financial position, results of operations and cash flows for all period presented, have been made. The results of operations for the interim periods presented are not necessarily indicative of the operating results for the respective full years.

Certain footnote disclosures normally included in the financial statements prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) have been omitted in accordance with the published rules and regulations of the Securities and Exchange Commission (“SEC”). These financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s annual report on Form 10-K for the fiscal year ended August 31, ~~2017~~2018 filed with the SEC on December 7, ~~2017 and a Post Effective Amendment No. 2 to a Form S-1 filed on April 4,~~ 2018.

The ~~basis is~~accompanying condensed unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ~~generally accepted accounting principles.~~of America (“U.S. GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”).

The accompanying condensed unaudited consolidated financial statements include the accounts of UBI Blockchain Internet Ltd. and its wholly owned subsidiary UBI Shenzhen Cross Border E-Commerce Co., Ltd, (“UBI Shenzhen”), formerly Shenzhen Nova E-commerce, Ltd. (“Nova”) from the date of acquisition of Nova on August 29, 2017 (see Note 4). All intercompany ~~accounts~~balances and transactions have been eliminated in consolidation.

The basic earnings (loss) per share of Class A, Class B and Class C common stock is calculated by dividing the Company’s net income (loss) available to Class A, Class B and Class C common shareholders by the weighted average number of Class A, Class B and Class C common shares issued and outstanding during the period. The diluted earnings (loss) per share of Class A, Class B and Class C common stock is calculated by dividing the Company’s net income (loss) available to Class A, Class B and Class C common shareholders by the diluted weighted average number of Class A, Class B and Class C shares outstanding during the period. The diluted weighted average number of Class A, Class B and Class C shares outstanding is the basic weighted average number of Class A, Class B, and Class C shares adjusted as of the first day of the period for any potentially dilutive debt or equity (none for the periods presented).

The Company considers all short-term investments with a maturity of three months or less at the date of purchase to be cash and cash equivalents.

Of the $189,323 cash at November 30, 2018, $182,969 was held in foreign bank account not insured by FDIC.

In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates.

Inventory, consisting of finished goods purchased from third parties, are stated at the lower of cost (first-in, first-out method) or market.

Property and equipment is stated at cost less accumulated depreciation. Depreciation is calculated on the straight-line basis over the estimated useful lives of the respective assets. Expenditures for repairs and maintenance are expensed as incurred.

~~Website~~Intangible assets, including website development costs, software acquired to be marketed, and office software, are carried at cost less accumulated amortization. ~~Website development costs will be~~Intangible assets are amortized using the straight-line method over anthe estimated economic ~~life~~lives of 5the respective assets (5 years ~~commencing on the date that the website is placed in service.~~

~~At February 28, 2018, the expected future amortization expense of~~for website development costs ~~is:~~

~~In January 2018, Nova changed~~and 5 years for the ~~domain name for its website fromwww.oyamall.com~~software acquired to~~www.hihealth8.com~~ be marketed and the office software). The change was made to, among other things, correct certain technical problems which we experienced in testing potential transactions involving Chinese currency. Nova’s website became operational on March 12, 2018.

~~Nova employs two people principally involved~~Software development costs include payments made to independent software developers under development agreements, as well as direct costs incurred for internally developed products. Software development costs are capitalized once technological feasibility of a product is established and such costs are determined to be recoverable. Technological feasibility of a product requires both technical design documentation and game design documentation, or the completed and tested product design and a working model. Significant management judgments and estimates are utilized in ~~website~~the assessment of when technological feasibility is established and the evaluation is performed on a product-by-product basis. For products where proven technology exists, this may occur early in the development cycle. Software development costs related ~~creation/maintenance activities. Nova’s expenses~~to hosted service revenue arrangements are ~~being funded by loans from Tony Liu.~~capitalized after the preliminary project phase is complete and it is probable that the project will be completed and the software will be used to perform the function intended. Prior to a product’s release, if and when we believe capitalized costs are not recoverable, we expense the amounts. Capitalized costs for products that are canceled or are expected to be abandoned are expensed in the period of cancellation. Amounts related to software development which are not capitalized are charged immediately to “Research and development”.

The reporting currency and functional currency of the Company is the United States Dollar.

The functional currency of ~~Nova~~UBI Shenzhen is the Chinese Renminbi (“RMB”). Assets and liabilities of ~~Nova~~UBI Shenzhen are translated into United States dollars at period-end exchange rates ($1.00 = ~~6.3276~~6.94577 RMB at ~~February 28,~~November 30, 2018 and $1.00 = 6.83750 RMB at August 31, 2018). ~~Nova~~UBI Shenzhen revenues and expenses are translated into United States dollars at weighted average exchange rates ($1.00 = ~~6.4450~~6.90730 RMB for the three months ended ~~February 28, 2018)~~November 30, 2018 and $1.00 = 6.60580 RMB for the three months ended November 30, 2017). Resulting translation adjustments are recorded as a component of accumulated other comprehensive income (loss) within stockholders’ equity.

The functional currency of UBI HK is the Hong Kong Dollar (“HK$”). Assets and liabilities of UBI HK are translated into United States dollars at period-end exchange rates ($1.00 = 7.8221 HK$ at November 30, 2018 and $1.00 = 7.8494 HK$ at August 31, 2018). UBI HK revenues and expenses are translated into United States dollars at weighted average exchange rates ($1.00 = 7.8351 HK$ for the three months ended November 30, 2018 and $1.00 = 7.8080 HK$ for the three months ended November 30, 2017). Resulting translation adjustments are recorded as a component of accumulated other comprehensive income (loss) within stockholders’ equity.

Transactions denominated in currencies other than the functional currency ~~(principally the Hong Kong Dollar)~~ are translated at the exchange rates prevailing at the dates of the transactions. Exchange gains and losses, which were not significant for the three ~~and six~~ months ended ~~February 28,~~November 30, 2018 and 2017 were reflected in income.

The provision for income taxes is the total of the current taxes payable and the net of the change in the deferred income taxes. Provision is made for the deferred income taxes where differences exist between the period in which transactions affect current taxable income and the period in which they enter into the determination of net income in the financial statements.

The Company recognizes revenue from services and product sales once all the following criteria for revenue recognition have been met: pervasive evidence that an agreement exists; the services or products have been delivered; the fee is fixed and determinable and not subject to refund or adjustment; and collection of the amount due is reasonably assured. ~~For the periods presented, the Company had no revenues.~~

The Company accounts for employee stock-based compensation in accordance with the guidance of FASB ASC Topic 718, “Compensation - Stock Compensation,” which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their fair values. The Company does not have an employee stock option plan.

The Company follows ASC topic 505-50, formerly EITF 96-18, “Accounting for Equity Instruments that are Issued to Other than Employees for Acquiring, or in Conjunction with Selling Goods and Services ,”,” for stock issued to consultants and other non-employees. In accordance with ~~ACS~~ASC Topic 505-50, the stock issued as compensation for services provided to the Company are accounted for based upon the fair value of the services provided or the estimated fair market value of the stock, whichever can be more clearly determined. The fair value of the equity instrument is charged directly to expense over the period during which services are rendered.

Related parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal with if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. The Company discloses all related party transactions.

Certain accounting pronouncements have been issued by the FASB and other standard setting organizations which are not yet effective and therefore have not yet been adopted by the Company. The impact on the Company’s financial position and results of operations from adoption of these standards is not expected to be material.

NOTE 4 – ACQUISITION OF UBI SHENZHEN CROSS BORDER E-COMMERCE CO., LTD (FORMERLY NOVA E-COMMERCE, LTD.)

On August 29, 2017, pursuant to an Acquisition Agreement dated May 16, 2017, the Company acquired 100% ownership of UBI Shenzhen Cross Border E-Commerce Co., Ltd. (“UBI Shenzhen”), formerly Shenzhen Nova E-commerce, Ltd. (“Nova”), in exchange for 25,000,000 shares of Company Class C common stock. ~~Nova~~UBI Shenzhen is a Shenzhen Chinese corporation which was incorporated on May 26, 2016. ~~Nova~~UBI Shenzhen plans on operating an online store in China selling a wide range of products.

The acquisition has been accounted for as a recapitalization transaction in the accompanying condensed unaudited consolidated financial statements. Accordingly, the financial position and results of operations of ~~Nova~~UBI Shenzhen prior to the August 29, 2017 date of acquisition have been excluded from the accompanying condensed unaudited consolidated financial statements.

The carrying values of the assets and liabilities of ~~Nova~~UBI Shenzhen at the August 29, 2017 date of acquisition consisted of:

The following proforma information (unaudited) summarizes the results of operations for the three and six months ended February 28, 2017 as if Nova was acquired on May 26, 2016 (Nova’s date of inception). The pro forma information is not necessarily indicative of the results that would have been reported had the transaction actually occurred on May 26, 2016, it is not intended to project results of operations for any future period.

Three Months Ended February 28, 2017 Six Months Ended February 28, 2017
(Unaudited) (Unaudited)

Revenue $ - $ -

Operating expenses:
Employee compensation (including stock - based compensation of $48,333 and $48,333, respectively) 202,223 250,275
Consulting fees (including stock - based compensation of $231,667 and $231,667, respectively) 231,667 256,667
Professional fees 8,147 39,516
Marketing 7,751 138,209
Occupancy 38,708 81,072
Other 10,410 31,227
Total operating expenses 498,906 796,966
Loss from Operations (498,906 ) (796,966 )
Other Income (expenses):
Gain on settlement of accounts payable and accrued liabilities 47,003 47,003
Gain on settlement of bank overdraft - 572
Net Loss $ (451,903 ) $ (749,391 )
Net Loss per share of Class A, Class B, and Class C common stock - basic and diluted $ (0.01 ) $ (0.02 )
Weighted average number of Class A, Class B, and Class C Common Shares outstanding - basic and diluted 55,217,046 49,250,195

Prepaid stock-based salaries and consulting fees at ~~February 28,~~November 30, 2018 and August 31, ~~2017~~2018 consist of:

At ~~February 28,~~November 30, 2018, there was ~~$863,333~~$308,333 of unrecognized compensation costs related to shares of Class A common stock issued to a consultant pursuant to a Consulting Agreement dated April 28, 2017 with a service term of two years expiring April 30, 2019. These costs are expected to be recognized as expense in the ~~years~~year ended ~~February 28, 2019~~August 31, 2019.

At November 30, 2018, the expected future amortization expense of the intangible assets was:

In January 2018, UBI Shenzhen changed the domain name for its website fromwww.oyamall.com towww.hihealth8.com. The change was made to, among other things, correct certain technical problems which we experienced in testing potential transactions involving Chinese currency. UBI Shenzhen’s website became operational on March 12, 2018.

UBI Shenzhen has yet to generate any revenues from its website. In order for UBI Shenzhen to begin its business operations, UBI Shenzhen will be selling third party products. In the future, management plans to develop its own products for sale. It was a management decision to acquire UBI Shenzhen for primarily two business reasons: 1) as a separate subsidiary, once UBI Shenzhen is fully operational, management anticipates it should generate revenues and profit for the Company; and 2) this acquisition provides a test model to utilize the blockchain technology the Company is developing to track drug products sold by UBI Shenzhen. As a test model, this will allow the Company to see if the products sold through its website are substituted with counterfeit products before they reach the final consumer. In other words, products sold through a third-party consumer will be tracked using the Company’s blockchain technology to see if there is a break in the supply chain. This will take place once the Company develops its blockchain digital tracking system. The Company will be able to monitor UBI Shenzhen shipments to the final consumer to determine if there has been any tampering with shipments in the supply chain.

UBI Shenzhen employs two people principally involved in website related creation/maintenance activities. UBI Shenzhen’s expenses are being funded by loans from Tony Liu.

On November 24, 2017, January 17, 2018 and March 15, 2018, UBI Shenzhen executed agreements with a third-party vendor to produce customized game software called Farmer Game for a total of RMB 285,000 ($~~740,000)~~41,682 using the August 31, 2018 exchange rate). UBI Shenzhen expects to use the Farmer Game to attract more visitors to its website and ~~quarter~~to potentially earn revenues from users’ use of game points to purchase products sold on the website. Farmer Game is expected to be introduced to website visitors in the near future.

In the year ended ~~May~~August 31, ~~2019~~2018, UBI Shenzhen paid the Farmer Game vendor a total of RMB 285,000 ($~~123,333).~~41,682), of which RMB 30,000 ($4,388) was expensed and RMB 255,000 ($37,294) was capitalized.

Pursuant to the September 15, 2016 change in control agreement (see Note 1), a representative of UBI paid into an attorney trust account $150,000 on September 14, 2016 and $67,500 on October 11, 2016, for a total of $217,500. The $217,500 consisted of $200,000 for the newly issued shares of Class A, Class B Voting, and Class C Common Stock and $17,500 for the payment of specific expenses.

Starting in December 2016, the Company engaged the services of a total of 45 employees and non-employees to perform certain marketing, research and development and investor relations services. The related agreements, which were executed in March 2017, ~~provide~~provided for the contractors to work for the Company for terms ranging from September 2016 to January 1, 2017 to December 31, 2017 for compensation including the issuance of a total of 8,400,000 shares of Class C common stock (which occurred April 3, 2017). Of the 8,400,000 shares, 5,000,000 shares were issued to Star Bright International Investment ~~Enterprises,~~Enterprise Limited, 100,000 shares were issued to the Company’s chief financial officer and 500,000 shares were issued to an independent Director of the Company.

The $1,680,000 estimated fair value of the 8,400,000 shares of Class C common stock (using a price of $0.20 per share) was recorded as prepaid expenses and was expensed evenly over the year ended December 31, 2017 (see Note 5). For the ~~six~~three months ended ~~February 28,~~November 30, 2018 and 2017, we recognized stock-based ~~salaries expense~~employee compensation of ~~$96,668~~$0 and $72,500, respectively and recognized stock-based consulting fees expense of ~~$463,332~~$0 and $347,500, respectively, from these agreements.

On May 1, 2017, the Company issued 500,000 restricted shares of Class A common stock to a consultant pursuant to a Consulting Agreement dated April 28, 2017 with a service term of two years expiring April 30, 2019. The $1,480,000 estimated fair value of the 500,000 shares of Class A common stock (using a price of $2.96 per share based on a $3.95 closing trading price on April 28, 2017 less a 25% restricted stock discount) was recorded as a prepaid expense and is being expensed evenly over the 2-year service period expiring April 30, 2019. For the ~~six months~~year ended ~~February 28,~~August 31, 2018, we recognized stock-based consulting fees expense of ~~$370,002~~$740,000 from this agreement. For the three months ended November 30, 2018 and 2017, we recognized stock-based consulting fees expense of $185,000 and $185,000, respectively, from this agreement.

On August 29, 2017, upon the regulatory approval of the transfer of Nova’s Hong Kong business license to the Company, the Company acquired 100% ownership of Nova in exchange for the Company’s issuance of a total of 25,000,000 shares of Class C common stock to the 130 owners of Nova.

On October 2, 2017, the Company issued a total of 82,000 restricted shares of Class A common stock to 4 individuals associated with the Company’s law firm for legal services rendered. The $335,872 estimated fair value of the 82,000 shares of Class A common stock (using a price of $4.10 per share based on a $5.12 closing trading price on October 2, 2017 less a 20% restricted stock discount) was expensed in the three months ended November 30, 2017.

On December 26, 2017, the Company’s Board of Directors approved a 3 for 1 common stock dividend of the Company’s issued and outstanding Class A and Class B common stock. On January 2, 2018, the Company was advised by FINRA to resubmit its request as a forward stock split instead of a stock dividend.

On January 4, 2018, the Company’s Board of Directors approved a 4 for 1 forward stock split for holders of record on January 10, 2018 of the Company’s issued and outstanding shares of Class A and Class B common stock. For each share of Class A common stock held, stockholders were to receive an additional 3 shares of Class A common stock, For each share of Class B common stock held, stockholders were to receive an additional 3 shares of Class B common stock. On January 18, 2018, the Company’s Board of Directors decided to cancel the proposed 4-for-1 forward stock split.

On January 5, 2018, the Securities and Exchange Commission announced the temporary suspension of trading in the Company’s securities from January 8, 2018 to January 22, 2018 because of (i) questions regarding the accuracy of assertions, since at least September 2017, by the Company in filings with the Commission regarding the Company’s business operations; and (ii) concerns about recent, unusual and unexplained market activity in the Company’s Class A common stock since at least November 2017.

On March 31, 2018, the Company’s Board of Directors approved issuing 150,000 Class C common unregistered restricted shares to Global Alliance Securities for consulting services. 150,000 Class C common shares were issued on August 30, 2018. The $30,000 estimated fair value of the 150,000 shares of Class C common stock (using a price of $0.20 per share) was expensed in the three months ended August 31, 2018.

~~As described in Note 9,~~At August 31, 2016, the Company was obligated to Mr. Mark DeStefano (“DeStefano”) for a $50,000 note payable and $26,981 for payments made on behalf of the Company. Subsequently, Mr. DeStefano advanced $1,285 to the Company. During the three months ended November 30, 2016 the Company satisfied these obligations. DeStefano had voting control of the Company from June 2014 ~~(see Note 9)~~ to October 24, 2016 (when the Company purchased from DeStefano the 1,000,000 shares of Preferred Stock for $33,735) through his ownership of the 1,000,000 shares of Voting Preferred Stock issued and outstanding (equivalent to 50,000,000 votes).

Commencing March 2017, the Company has been using office space provided by an affiliate of UBI Blockchain Internet, LTD. (Hong Kong) (“UBI Hong Kong”) at a monthly rent of 22,100 Hong Kong Dollars (approximately ~~$2,824~~$2,825 at the ~~February 28,~~November 30, 2018 exchange rate) per month. For expediency reasons, the Company also uses bank accounts in the name of UBI Hong Kong to collect cash receipts and expend cash disbursements relating to Company operations. UBI Hong Kong owns 30,000,000 shares of the Company’s Class A common stock.

InDuring the ~~six~~three months ended ~~February 28,~~November 30, 2018, Tony Liu, chief executive officer of the Company, advanced or paid a total of ~~$692,079~~$413,054 of expenditures on behalf of the Company. As of ~~February 28,~~November 30, 2018, the total amount due to Tony Liu was ~~$1,247,578.~~$2,365,721. The amount due to Tony Liu for these expenditures is interest bearing at a rate of 7% per annum. ~~$18,019~~$34,781 and ~~$28,845~~$10,826 interest expense was accrued for the three ~~and six~~ months ended ~~February 28,~~November 30, 2018 and 2017, respectively. As of ~~February 28,~~November 30, 2018, accrued interest amounted to ~~$39,456.~~$126,250. The advances and related accrued interest are due on demand.

Included in accounts payable and accrued liabilities at November 30, 2018 and August 31, 2018 is accrued salary due to Tony Liu, chief executive officer, $63,154 and $62,744, respectively.

The Company accounts for income taxes under FASB Accounting Standard Codification ASC 740 “Income Taxes”. ASC 740 requires use of the liability method. ASC 740 provides that deferred tax assets and liabilities are recorded based on the differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes, referred to as temporary differences. Deferred tax assets and liabilities at the end of each period are determined using the currently enacted tax rates applied to taxable income in the periods in which the deferred tax assets and liabilities are expected to be settled or realized.

As of ~~February 28,~~November 30, 2018 and August 31, 2018, the Company had net operating loss carry forwards of approximately ~~$2,085,872 that~~$3,174,000 and $2,883,000, respectively, as follows:

United States net operating losses prior to 2018 may be ~~available~~carried forward to reduce future ~~years’~~years taxable income ~~through 2037.~~for 20 years; United States net operating losses after 2017 may be carried forward indefinitely. Hong Kong net operating losses may be carried forward indefinitely. China net operating losses may be carried forward for 5 years. Future tax benefits which may arise as a result of these losses have not been recognized in these financial statements as their realization has not been determined likely to occur. Also, due to the change in control, there are annual limitations on future United States net operating loss carry forward deductions.

At ~~February 28,~~November 30, 2018 and August 31, ~~2017,~~2018, deferred tax assets consisted of:

As a result of the ~~tax~~Tax Cuts and Jobs Act enacted on December 22, 2017, the United States corporate income tax rate iswas reduced from 35% to 21% effective January 1, 2018. Accordingly, we ~~have~~ reduced our deferred income tax asset relating to our United States net operating loss carryforward (and the valuation allowance thereon) by ~~$292,022 from $730,055 to $438,033 as of February 28, 2018.~~approximately $243,280 on December 31, 2017.

~~On April 4, 2014, the~~The Brewing Company issued a One-year Promissory Note (“the Note”) in the amount of $50,000 to Mark DeStefano (“DeStefano) (see Note 7). The Note bore interest at 12% percent per annum with interest due each month. In the event that interest was not paid within three days from the time it was due the Note was to be considered in default and was to be fully due and payable. Additional consideration for the Note included the Chief Executive Officer of the Company giving the note holder his voting proxy for all of the shares he held with the exception of voting on a tender offer or a sale of the Company’s assets. As of May 8, 2014, the Note was in default.

On May 5, 2014, the Company issued a second One-Year Promissory Note (“the Second Note”) in the amount of $20,000 to the same stockholder noted above. The Second Note was issued with the restriction that the funds be used specifically to pay the Company’s Patent Counsel for fees to finalize certain patent filings and was secured by all patents and patent applications held by the Company. The Second Note was to bear interest at 12% percent per annum with interest due each month. In the event that interest was not paid within three days from the time it was due, the Second Note would be considered in default and would be fully due and payable.

On June 6, 2014, the Company received notices that it was in default of the two Promissory Notes described above. Rather than default on the Notes, the Company issued 1,000,000 shares of $0.001 par value Voting Preferred Stock in exchange for Notes Payable totaling $20,000 plus forgiveness of interest totaling $1,900. Additionally, the Company agreed to designate with the State of Nevada Secretary of State that each share of preferred carries the voting power of 50 common shares. Finally, the shareholder agreed to cancel the shares upon full payment of the $50,000 Note, without accrued interest and the sale of five units of the MDU.Agreement

~~During the three months ended November 30, 2016, the Company settled a bank overdraft of $942 for $370. This settlement resulted in income of $572.~~

~~On January 27, 2017,~~August 2018, the Company entered into a ~~Settlement~~development agreement, by and among the Company, Heilongjiang Province TongFangZhuoXin Brewing Co., Ltd. (the “Brewing Company”) and Global Blockchain Cooperation Alliance, dated August 26, 2018 (the “Brewing Company Agreement”). Pursuant to the terms of the Brewing Company Agreement, the Company agreed to provide to the Brewing Company blockchain based technology and software for the management of the Brewing Company’s manufacturing process. In exchange for the services and technology provided by the Company, the Brewing Company agreed to pay to the Company a total of RMB 7,000,000 (approximately $1,007,808), which is payable over the term of the Brewing Company Agreement in a series of milestone payments. The Company received the initial payment of RMB 400,000 (RMB 388,350 net of tax or approximately $56,223) on September 30, 2018. The balance is payable in a series of 8 payments ranging from RMB 300,000 (approximately $43,192) to RMB 1,500,000 (approximately $215,959) from time to time as each milestone is completed over a period of 27 months, with the final payment being due on or before December 31, 2020. Any disputes between the parties are to be submitted to the Beijing International Arbitration Center. The Brewing Company Agreement provides for a ~~former landlord satisfying~~breach penalty in an amount equal to 5% of the contract amount in the event that either party defaults in its obligations pursuant to the Brewing Company Agreement.

The Company recognizes revenue under this agreement as its performance obligations under each milestone of the agreement are completed. At November 30, 2018, the Company’s performance obligations of the Phase 1 Period 1 milestone (relating to the RMB 400,000 initial payment) have been completed. At November 30, 2018, the Company has no contract assets or contract liabilities relating to this agreement.

In August 2018, the Company entered into a ~~$35,868 accrued liability~~development agreement, by and between the Company and Harbin Madieer Hotel Group Co., Ltd. (the “Hotel Group”), dated August 26, 2018 (the “Hotel Group Agreement”). Pursuant to the terms of the Hotel Group Agreement, the Company agreed to provide to the Hotel Group a blockchain based system for ~~$4,100. This settlement, along~~hotel management. In exchange for the services and technology provided by the Company, the Hotel Group agreed to pay to the Company a total of RMB 1,000,000 (approximately $143,973) which is payable over the term of the Hotel Group Agreement in a series of milestone payments. The initial payment of RMB 400,000 (RMB $388,350 net of tax or approximately $56,222) was received on November 12, 2018. The balance is payable in a series of 3 payments ranging from RMB 300,000 (approximately $43,192) to RMB 400,000 (approximately $57,589) from time to time as each milestone is completed, over a period of 11 months, with the final payment being due on or before July 31, 2019. Any disputes between the parties are to be submitted to the Beijing International Arbitration Agency or a People’s Court of the Hotel Group’s location. The Hotel Group Agreement provides for a breach penalty in an ~~arrangement with another vendor, resulted~~amount equal to 5% of the contract amount in ~~other income~~the event that either party defaults in its obligations pursuant to the Hotel Group Agreement.

The Company recognizes revenue under this agreement as its performance obligations under each milestone of ~~$47,003.~~the agreement are completed. At November 30, 2018, the Company’s performance obligations of the Phase 1 Period 1 milestone (relating to the RMB 400,000 initial payment) have been completed. At November 30, 2018, the Company has no contract assets or contract liabilities relating to this agreement.

On January 10, 2018, the Company announced that the Hong Kong Special Administrative Region (“HKSAR”) approved in principle a grant of up to HK$3,018,750 (approximately ~~$385,000)~~$386,000) to assist in financing a project entitled “Blockchain-Based Food and Drug Counterfeit Detection and Regulatory System” (“the HKPU Project”) to be jointly developed by UBI Hong Kong and The Hong Kong Polytechnic University (“HKPU”). The related agreement also provides for UBI Hong Kong to contribute up to HK $3,018,750 (approximately ~~$385,000)~~$386,000) to the project cost in installments with the first installment of HK$561,198 (approximately $72,000) due upon HKSAR’s signing of the agreement (which occurred on January 5, 2018). UBI Hong Kong owned and controlled by Tony Liu, is the largest Class A Common Stock shareholder of UBI Blockchain Internet, Ltd., (Delaware). Although the Company does not own or control UBI Hong Kong, UBI Hong Kong entered into an Assignment Agreement with UBI Delaware on May 1, 2018, whereby UBI Hong Kong assigned all of its rights, plans, ideas, tangible assets, intangible assets and intellectual property under the HKPU Project agreement to UBI Delaware, in order for UBI Delaware to commercialize the technology being developed. The project is expected to be completed by November 14, 2019. In a series of two payments made by UBI Hong Kong on January 12, 2018 and January 16, 2018, UBI Hong Kong paid its first installment of a total of HK$561,198 (approximately ~~$71,000)~~$72,000) to HKPU. On February 1, 2018, HKSAR paid its first installment of HK $561,198 (approximately ~~$71,000)~~$72,000) to HKPU. At this point, the project is progressing on track, and the parties believe the established budget will be sufficient to complete the project.

The agreement also provides for UBI Hong Kong to pay the remaining HK $2,457,552 (approximately $314,000) of its installments as follows: HK $687,934 (approximately $88,000) by April 1, 2018; HK$687,934 (approximately $88,000) by October 1, 2018; HK $687,934 (approximately $88,000) by April 1, 2019 and HK$393,750 (approximately $50,000) within three months of the completion of the HKPU Project. ~~To date,~~On May 11, 2018, UBI Hong Kong paid HKPU a second installment of HK $643,647 (approximately $82,000). On May 24, 2018, HKSAR also paid HKPU a second installment of HK $643,647 (approximately $82,000). While UBI Hong Kong does not have the financial wherewithal to pay current installments under the agreement as due, Tony Liu has ~~not yet paid~~personally agreed and been able to provide funding as necessary for both operations of the ~~HK $687,984 (approximately $88,000) installment~~Company and obligations due ~~April 1, 2018.~~under the agreement.

The agreement also provides for the HKSAR to pay the remaining HK $2,457,522 (approximately $314,000) of its installments periodically within 30 days after the acceptance by the Commissioner of Innovation and Technology (“CIT”), an agency of the HKSAR, of certain Progress Reports to be submitted periodically by HKPU. The agreement provides that HKPU should provide CIT the first written Progress Report in a format acceptable to CIT covering from the Commencement Date to August 31, 2018 to be submitted on or before September 30, 2018. ~~While no~~The first written ~~Progress Reports have yet been required or provided~~progress report was timely submitted by UBI Hong Kong and HKPU to ~~CIT, periodic telephone conversations with CIT have occurred between CIT, HKPU, and the Company from time to time concerning HKPU Project’s progress.~~CIT. The agreement imposes no penalties on UBI Hong Kong should it fail to make any of its installment contributions except that HKSAR principally has the right to cease their installment contributions if UBI Hong Kong fails to make its installment contributions. HKSAR may terminate the agreement if UBI Hong Kong fails to make any of its installment contributions. Further, if any of the parties are in breach of the terms of the agreement or fail in a material way to progress in accordance with the Project Proposal, HKPU shall on demand by the government pay to the Government an amount equivalent to the funds or portion thereof released for the Project.

The goal of this project is to provide a comprehensive solution to the worldwide problem of counterfeit medicines. Leveraging latest techniques the team wants to develop a low-cost, scalable, secure system for: (1) Manufacturers to record necessary data of the drugs during their production and transportation; (2) Distributors to trace the drugs; (3) Auditors to inspect all data; and finally (4) Consumers to verify the authenticity of the purchased product. This platform will provide suppliers of food and drug products a safety control system to determine if there was a break in the supply chain. It will identify if a product was substituted with a counterfeit or inferior product. It will help suppliers of perishable food products, reduce spoilage by tracking food shipments in the supply chain to the final consumer.

In February 2018, UBI Hong Kong performed a test at the offices of Guangxi Houde Mega Health Enterprise (“Guangxi”), a medical products company, of the e-commerce “alpha” platform (using simulated test data provided by Guangxi). Guangxi is owned 70% by Star Bright International Investment Enterprise ~~Ltd., (“Star Bright”). Star Bright owns~~Limited, owner of 5,000,000 shares of ~~UBI Delaware~~Company Class C ~~common stock~~Common Stock (see Note 6)7). The test identified some technical issues that need to be addressed; the team is currently preparing for a second test, ~~has been~~the second test, originally scheduled for June ~~2018.~~2018, will not be scheduled until the team believes the test will be successful. The e-commerce platform will provide a digital shared accounting ledger that would make it possible to trace back a product to the very origin of the raw material used.

Once a working model of a platform is successfully operational, the Company ~~intends~~plans to ~~sell~~license the ~~software~~technology to larger food and drug third party ~~customers.~~customers, in which case the licensee can use it in accordance with the license agreement; and the Company also intends to provide the technology, when commercial ready, to third party suppliers as a paid service.

The agreement provides that the equipment acquired from the HKPU Project will belong to HKPU, who is also identified as the Beneficiary of the grant for the project and is required to provide CIT with interim and a final accounting for the proceeds of the grant as well as monies advanced by UBI Hong Kong whether the project is successful or not. While HKPU, as the Beneficiary, is provided discretion on how income arising from the intellectual property rights from the Project Materials (including among other things computer software/programs, technical materials, models, documents and materials compiled developed, produced or created by or on behalf of the Beneficiary – the ~~“platform.”~~“platform”) and Project Result is to be allocated, UBI Hong Kong is the sole and absolute beneficial owner (has title to) of all of the intellectual property rights which would include the platform if successfully completed under the project. ~~However, there is no written~~

While HKPU receives full legal and equitable title and interest in any and all of the equipment procured by the Beneficiary, the agreement ~~between UBI Delaware and~~does not discuss whether HKPU can discontinue its own performance in the event that either HKSAR or UBI Hong ~~Hong~~Kong fail to make the required payments. However, without funding no one would expect that ~~provides for title~~HKPU would be obligated to ~~the platform being conveyed to UBI Delaware.~~continue its performance.

The agreement also has ~~provisions~~a provision whereby the HKSAR can terminate the grant under certain conditions. These conditions include, among other things, ethical misuse of funds received under the grant or violations of other requirements under the grant. This would include UBI Hong Kong’s failure to meet its general financial obligations as due or go into liquidation. In the event of termination, the HKSAR has the right to suspend payment under the grant or require that amounts previously paid by it be refundable under the grant.

The Company expects to use the technology learned from the HKPU Project to help it develop and market a platform system for application to control and manage the safety of food and drugs. Pursuant to an understanding with UBI Hong Kong, the Company is responsible for the installments due and other costs relating to the HKPU Project paid by UBI Hong Kong. These costs are expected to be paid by UBI Hong Kong from loans received from the Company’s CEO Tony Liu. The Company ~~has charged the first installment paid by UBI Hong Kong in January 2018 ($71,779) and expects to record future installment payments~~records these costs as research and development expenses and increases in amounts due to Tony Liu until such time as a “technologically feasible” working model of the platform has been successfully produced.

The Company plans to commercialize our blockchain technology, by selling suppliers of food and drug products a blockchain technology platform to track the shipping of their products from its source to the final consumer with tamper-resistant digital records that replaces the current related shipping paperwork. There are two ways we plan to commercialize the technology: 1) to license the technology to third parties, in which case the licensee can use it in accordance with the license agreement; and 2) UBI to provide the technology to third party suppliers (the supplier will pay for each use). The goal is to license our blockchain technology to streamline record-keeping for the food and drug supply chain. We also plan to provide blockchain technology, when commercial ready, to suppliers as a paid service. Our goal is to design a blockchain tracking system that eliminates counterfeit drug products being substituted in the supply chain. And, with regards to food products where lost or delayed shipments causes perishable goods lying in wait to spoil, our blockchain tracking is being designed to help expedite and monitor physical transportation. It is management’s goal to have this technology ready for commercialization soon after the fiscal year ending August 31, 2019.

Management believes that blockchain technology along with the capabilities of tamper resistance products can help bring about new safety standards for the health industry. This makes blockchain technology worthy of our research and investment. It is for this reason management made the decision to establish a company to research and develop blockchain technology. In order to achieve its goals, management is working to design a product tracking system, where every step a product takes in its supply chain is recorded, time-stamped and monitored to protect the integrity of the product(s) being shipped from its source to the final consumer. This is accomplished by tracing the movement of the product from its origin to its final consumer. Utilizing blockchain technology, every time the product moves, its location is recorded and time-stamped, and a shared accounting ledger can be reviewed to determine if there was a break in the supply chain, to see if the product was substituted with a counterfeit or inferior product.

UBI’s business strategy is to incorporate the research and application of blockchain technology, Internet of Things (“IoT”), pharmaceutical and food products, which together, we refer to as IBSH platform. We have hired professional and technical personnel to develop a working platform. With the development and research on the platform, we plan to build a blockchain based safety control system, tentatively named “UBI Security Shield”, with its first application to be used for food and drug safety

In September 2017, ~~Nova~~UBI Shenzhen entered into two lease agreements for office space in Shenzhen ~~China, the~~China. The first lease provides for monthly rent of RMB 12,353, or approximately ~~$1,952~~$1,778 per month, and expires September 2020. The second lease provides for monthly rent of RMB 8,964, or approximately ~~$1,417~~$1,291 per month, and expires September 2019.

As of ~~February 28,~~November 30, 2018, the future minimum lease payments under non-cancelable operating leases were:

For the three ~~and six~~ months ended ~~February 28,~~November 30, 2018 and 2017, total rent expense was ~~$23,069~~$32,653 and ~~$39,690~~$16,621, respectively.

The offer and sale of the 25,000,000 Class C Common Shares for the acquisition of UBI Shenzhen may have been in violation of the rules and regulations under the Securities Act and the interpretations of the SEC. The possible violation involves whether the Company conducted a public offering without providing the former UBI Shenzhen shareholders with a registration statement declared effective by the SEC. If a violation of the Section 5 of the Securities Act did in fact occur, anyone who acquired Class C Common Shares at a price based on an evaluation of $0.20 per share would have a right to rescind the purchase. The Securities Act generally requires that any claim brought for a violation of Section 5 of the Securities Act be brought within one year of the violation. If all the shareholders who acquired Class C Common Shares for their exchange in the ownership of UBI Shenzhen demanded rescission within that one-year period and prevailed in their claims, we would have potentially been obligated to repay approximately $5,000,000.

In the opinion of management and company counsel, the likelihood of any of the former UBI Shenzhen shareholders making a claim for a violation of Section 5 of the Securities Act is remote because the effected shareholders are all Chinese citizens who have a close knit relationship with each other and who all voted in favor of the Company’s acquisition of UBI Shenzhen. None of these effected shareholders have made any claim to date and the one-year period that they had to bring a claim expired August 29, 2018.

On December 10, 2018, UBI Hong Kong Paid HKPU a third installment of HK$ 653,647.55 (approximately $84,000) required under the HKPU project agreement (see Note 11).

Item 2. - Management’s Discussion and Analysis of Financial Condition and Results of Operations

This Quarterly Report on Form 10-Q contains forward-looking statements. When used in this Quarterly Report on Form 10-Q, the words “may,” “could,” “estimate,” “intend,” “continue,” “believe,” “expect” or “anticipate” and similar expressions identify forward-looking statements. Although we believe that our plans, intentions, and expectations reflected in any forward-looking statements are reasonable, these plans, intentions, or expectations may not be achieved. Our actual results, performance, or achievements could differ materially from those contemplated, expressed, or implied, by the forward-looking statements contained in this Quarterly Report on Form 10-Q. Important factors that could cause actual results to differ materially from our forward-looking statements are set forth in this Quarterly Report on Form 10-Q. Accordingly, readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the dates on which they are made. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth in this Quarterly Report on Form 10-Q, except as required by federal securities laws, we are under no obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Although we believe that the expectations reflected in any of our forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change and inherent risks and uncertainties.

In this Quarterly Report on Form 10-Q references to “UBI Blockchain Internet Ltd.,” “JA Energy,” “UBI Blockchain Internet, Ltd., formerly known as JA Energy,” “UBI,” “the Company”, “we,” “us,” and “our” refer to UBI Blockchain Internet Ltd. ~~(a Delaware Company).~~

There have been no material changes to our critical accounting policies and estimates from the information provided in Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations”, included in our Annual Report on Form 10-K for the fiscal year ended August 31, 2017 filed with the Securities and Exchange Commission on December 07, 2017.

The Company was ~~organized~~incorporated in Nevada on August 26, 2010, ~~(Date of Inception)~~ under the ~~laws of the State of Nevada, as JA Energy. The Company was incorporated~~name “JA Energy,” as a subsidiary of Reshoot Production Company, a Nevada ~~corporation.~~corporation, incorporated October 31, 2007. In May, 2011, Reshoot Production Company ~~was incorporated October 31, 2007, and, at~~spun off the ~~time of spin off was listed on the Over-the-Counter Bulletin Board.~~Company to its shareholders.

From August 2010 to May 2014 the Company was in the business of designing a suite of modular, self-contained, fully automated, climate controlled units for distributed production of energy. While some of these products were proven to be technologically viable, none were ever developed to the point where they were ready for introduction to the marketplace.

In October 2014, pursuant to the ~~Board~~terms of ~~Directors approved~~an Irrevocable Asset and Liability Exchange Agreement, dated as of October 15, 2014, by and among the ~~formation~~Company, James Lusk, Mark DeStefano and T.J. Jesky, the Company transferred all of ~~a new company called~~its assets and liabilities to its wholly owned subsidiary, Peak Energy Holdings, a Nevada corporation ~~where each shareholder in~~(“Peak”) and Peak issued to the ~~Company received~~Company’s shareholders, one share of Peak common ~~of Peak Energy Holdings~~stock for each share of common stock owned in the Company and one share of Peak preferred stock ~~of Peak Energy~~ for each share of preferred ~~share~~stock owned in the ~~Company. As part of~~Company (the “Spin-Off”). Following the ~~transaction, the Company spun-off all of its assets and liabilities into~~Spin-Off, Peak ~~Energy. Further, the spin-off subsidiary~~ operated as an independent entity separate ~~entity~~ from the Company with new ~~management operating the current core business of Peak Energy for the benefit of the original stockholders.~~management. The ~~effect of this action~~Spin-Off allowed the Company to explore new business opportunities without the burden of the assets and liabilities on the corporate books.

In September 2016, the Company established its headquarters in Hong Kong, and issued 30,000,000 shares of unregistered restricted Class A Common Stock, 6,000,000 shares of unregistered restricted Class B Voting Common Stock, which carries a voting weight equal to ten (10) Common Shares, and 40,000,000 shares of unregistered restricted Class C Common Stock to UBI Blockchain Internet, LTD (“UBI Hong Kong”), in exchange for $200,000. UBI Hong Kong is beneficially owned and controlled by Tony Liu our CEO and as a result of the transaction UBI Hong Kong and Tony Liu became controlling shareholders of the Company. Thereafter, the Company’s business focus was dedicated to the application of the blockchain technology to safety issues arising out of counterfeit and inferior substitute products and services in the Chinese health industry.

On November 21, 2016, the Company changed its corporate name from JA Energy (“JA”) to UBI Blockchain Internet, LTD, and changed ~~the~~its state of incorporation from the State of Nevada to the State of Delaware pursuant to a plan of conversion ~~in connection with~~about which the Company adopted a new certificate of incorporation under the laws of the State of ~~Delaware.~~Delaware after UBI acquired a controlling equity in JA and this transaction was treated as a reverse merger for accounting purposes.

On May 16, 2017, the Company acquired 100% ownership of Shenzhen Nova E-commerce, Ltd., a private Shenzhen Chinese corporation in exchange for 25,000,000 unregistered restricted Class C common shares. In April, 2017 Shenzhen Nova E-commerce began its operations of an online store in China selling a wide range of products including maternal and infant products, cosmetics, wine, household goods, digital and luxury products. Nova became a wholly owned subsidiary of the Company. It was a management decision to acquire Nova for primarily two business reasons: 1) as a separate subsidiary, once NOVA is fully operational, it should generate revenues and profit for the Company; and 2) this acquisition provides a test model to utilize the blockchain technology the Company is developing to track drug products sold by NOVA.

UBI Blockchain Internet Ltd. business encompasses the research and application of blockchain technology with a focus on the Internet of things covering areas of food, drugs and healthcare. Management plans to focus its business in the integrated wellness industry, by providing procedures for safety and effectiveness in food and drugs, but also preventing counterfeit or fake food and drugs. With the advancement of the blockchain technology, the Company plans to trace a food or drug product from its original source within the context of the internet of things to the final consumer.

When UBI was first formed, management established a goal and mission to solve the safety and quality issues of food and drugs using blockchain technology. This is a been an on-going problem, especially in China. For a number of years, management has observed, first-hand, the rampant counterfeit and inferior quality problems in the Chinese health industry, where food and drugs constitute the majority of products.

UBI’s Blockchain Internet business includes research and application of blockchain technology, which includes Internet of Things (“IoT”) technology, pharmaceutical research and manufacturing technology for the health industry, and platform trading technology for the financial capital markets, which together, we refer to as IBSH technology. These technologies include well-established technologies, such as Big Health Industry Technology and Financial Capital Market Technology. There are also emerging, forward-looking, technologies such as blockchain and IoT technologies. We are familiar with big health and financial capital markets; however, we are not yet familiar with blockchain and the Internet of Things. We have matured in the above-mentioned technology when it comes to health and financial capital of the part. For the other part, we have hired professional and technical personnel to conduct research and master the same time, and universities and other research institutions to discuss cooperation and establish a joint R & D center platform. IBSH technologies will be our core focus technologies. They will become our patented intellectual property. With the development of our technologies, we will conduct systematic research integration, development of a complete set of safety control system, tentatively named “UBI Security Shield” which will be first applied to food and drug safety control.

~~UBI has formed a research team dedicated to the application and research of IBSH technology to achieve the company’s business goals.~~

IBSH technical definition: The blockchain, Internet of things, big health industry, financial capital market technology integration technology. Our technology has two major characteristics: First, the forward-looking and innovative technology, blockchain and the Internet of things is a technology for the future world with forward-looking and innovative technologies. Second, management believe the commercial value of our technology will have a strong practical application and it will combine with the industry to deliver a commercial value.

Blockchain, refers to a distributed database that is used to maintain a continually growing list of ordered records (called blocks). Each block contains a timestamp and a link to the previous block. Blockchain has the characteristics of “decentralization” and “tamper-proof”.

Internet of Things, embedded physical devices, vehicles (also referred to as “networking devices” and “smart devices”), buildings and other objects embedded in electronic technology, software, sensors, and brakes are connected via the Internet and enable these objects to collect and exchange data for network connectivity. IoT allows remote sensing or remote control of objects through existing network infrastructures to create opportunities for more direct integration of the physical world into computer-based systems and to increase efficiency, accuracy and economic scale.

Our interest is to develop a safety control system, to control the quality of raw materials for food and drugs, to control the standardized manufacturing process, and to control inventory warehousing. The safety and quality control are achieved by the blockchain technology, which is tamper resistant and decentralized. Our research on the application of the blockchain technology remains focused on the implementation of the blockchain network, private blockchain configuration and development, a Blockchain Explorer, smart contract for the supply chain.

Recent advances in streamlining video, monitoring sensors, high-speed broadband internet, introducing wireless standards (such as Bluetooth low-power) and other technologies have brought about the emergence of virtual transactions and investment plans that individuals and businesses can base on their spending habits to measure data that monitoring equipment and applications to receive real-time feedback and to fit a wide range of personal and corporate preferences for reliability at home.

Blockchain techniques have shown considerable adaptability in recent years, as various market sectors have sought to find ways of incorporating capabilities into their operations. While most of the focus has so far been on financial services industry, this has begun to change. For example, the use of blockchain technology to support digital electronic payments to counter counterfeit drugs in the pharmaceutical industry. The adaptability of blockchain to a large number of applications has been one of the driving forces of the technology’s growing interest in past few years. As solution for organization and ledger needs, the most recent market for blockchain technology is pharmaceutical industry.

The use blockchain technology and internet of things is being employed to address universal healthcare industry regarding food and drug safety and labor relations management. At present, management believes that there exists confusion of Chinese medicine industry including fake drugs, bad medicine serious phenomenon, no regulated production, no guaranteed efficacy of traditional Chinese medicine. The excessive use of antibiotics, poison capsules incidents, vaccine cases ginkgo leaf, licorice tablets and other major drug cases, have seriously affected people’s physical and mental health. Therefore, food and drug safety relates to vital interests of millions of people’s social problems. From current safety issues of food and drug, we see scientific and exact drug management issues.

Management believes that the blockchain technology and internet of things promote industrial information and emergence of possible technological solutions. Through integration of blockchain technology for the core of internet of things to establish a seamless industrial chain so as to achieve food and drug safety control and enterprise relations management. Internet of Things is the extension and continuation of internet. IoT can increase the ubiquity of the internet by integrating every object for interaction via radio frequency identification (RFID) devices, infrared sensors, global positioning systems, laser scanners and other information sensing equipment, which leads to a highly distributed network of devices communicating with human beings as well as other devices. IoT is opening opportunities for a large number of novel applications that promise to improve quality of lives. In recent years, IoT has connected with blockchain, exchange and communication for intelligent identification, location, tracking, monitoring and management of a network. This technology is still in its infancy.

A universal healthcare system covers all citizens seeking to achieve efficiencies by integrating the basic functions of healthcare delivery, health insurance, distribution of healthy food and drug safety and labor relations management. Based on the full integration of internet of things with blockchain technology, this technology can change old systems. Blockchain technology is a distributed database that maintains a continuously-growing list of records called blocks. Each block contains a timestamp and a link to a previous block. The data in a block cannot be altered retrospectively. Blockchain has characteristics such as decentrality, openness and transparency, autonomy, security of information that cannot be tampered with, and anonymity, these features can strengthen solution to drug and food safety issues, as well as getting more meaningful solution to enterprise labor relations management.

Management plans to focus its business in the integrated wellness industry, which providing procedures for safety and effectiveness in food and drugs, but also preventing counterfeit or fake food and drugs. With the advancement of the blockchain technology, we can trace a food or drug product all the way up to its original source within the context of the internet of things.

We are now in the early stages of blockchain technology, but we have good research, technical framework design, industry language and IT language conversion recognition of how blockchain and IoT interface with food and drug technology. Soon, we will utilize the technology in food and drug safety control.

Blockchain technology has a very wide range of potential applications. Blockchain is a distributed ledger agreement that allows projects or transactions to be registered in a transparent manner and was originally developed for use in various industries to provide a wide range of services including banking, stock trading, real estate and even worldwide diamond sales. More and more financial giants are joining blockchain technology applications, research and development, including IBM, Microsoft, Intel, Blockstream and Thomson Reuters to accelerate further Blockchain technology as a development system. As the blockchain technology is becoming mature and secure, it can play a role in many areas and management believes that the application area and development potential of blockchain technology provide the Company with an opportunity to grow.

UBI management believes the global IoT in the healthcare market is growing at a significant rate of growth due to the growing demand for advanced healthcare information systems and the growing prevalence of chronic diseases and lifestyle-related diseases.

The IoT applications in healthcare, such as telemedicine, medication management, clinical operations and workflow management, inpatient monitoring, helps in compiling services related to diagnosis, treatment, care, and rehabilitation. They improve communication between patients and healthcare workers, reducing medication errors, and providing better coordinated care.

Blockchain and the Internet of Things are technologies that affect the future. UBI Company took the lead in entering this market. First, using IBSH technology in the big health industry, will help position the company in this field. The standard of this market access is hard and the cost is high. The UBI team is optimistic about the future.

Blockchain technology can play a role in many fields. Blockchain transactions are theoretically real-time. The block-based distributed accounting technology, combined with its artificial intelligence and internet of things technologies, makes it possible for countless of smart technologies to connect to internet for greater security, allowing technicians to return to the point at which the problem occurred. One of potential applications of this technology is the creation of registers based on blockchain of IoT devices, and the use of artificial intelligence programs to perform automated intelligent diagnostics and more advanced functions, which can ultimately lead engineers and technicians to virtualize clock backwards. At the same time, blockchain technology can reduce audit costs; reduce distrust of central node, so that flow of financial assets is more transparent and convenient. In fact, current blockchain technology is indeed application of digital electronic payments to “block chain +” transition extension from financial sector gradually to IoT and other non-financial areas which will trigger more and greater industrial restructuring and revolution.

The internet of things is based on computer science, including network, electronics, radio frequency, induction, wireless, artificial intelligence, bar code, cloud computing, automation, embedded technology as an integrated technology. Internet of things is called the third wave of the world information industry revolution, after computer revolution, and the second internet revolution. Management believes that within 10 years, internet of things will be widely used in intelligent medicine, intelligent transportation, environmental protection, government work, public safety, safety home, intelligent home appliance, industrial monitoring, elderly care, personal health, intelligent building, green agriculture and breeding, surveillance, imaging, computers, mobile phones and other fields.

Blockchain technology is a good solution for: infrastructure investment, high maintenance costs and data security issues. Blockchain technology supports IoT which is an extension and more advanced stage of internet. Blockchain technology research and application will make IoT networking more efficient. Blockchain technology creates a shared, distributed, digital book between network nodes to record transactions, rather than storing them on a central server. This eliminates the need for central verification. It provides a way to create a consensus network without having to trust a single node, and data store does not need to be stored in a central server, but by sharing it to all nodes in network. Blockchain technology can also solve medical field of data privacy and other issues, such as custody of electronic medical records, safe storage of genetic data, and drug security.

Our Group will plans to grasp the new technologies that will affect the future world, establish a new business model based on the industrial and capital advantages that we have already formed, and create the technical advantages of UBI’s IBSH. Managements wants UBI to become a world leader in excellence. Management expects it will take three years to develop a business breakthrough and five years in making an essential achievement.

Our growth strategy depends to a large extent on our ability to reach potential customers who successfully bring their products to target markets. We plan to initially target the China market and gradually expand to Europe and the United States and beyond.

At present, we have initially established the technical framework and the core of the main body, with the combination of food and drug use, access to our first phase of research and experimental results, that can be practical applications, and continuous technological upgrading.

UBI’s planned first product will be a food and drug safety monitoring and control system. It will also be our core product. At the same time, we plan to systematically develop healthy big data and cloud computing, food products, health and service products, cross-border e-commerce platform and global health and culture platform.

~~We plan to position the Company’s marketing as creating and building a corporate brand image globally. All this will start in China .~~

~~We plan to hire professionals from all over the world. Together to create UBI a shared platform.~~

We believe that international markets represent a significant growth opportunity for us and we intend to expand sales of our intended products and services globally through selected retailers and strategic partnerships. We plan to work with key partners in the target markets to provide marketing and distribution expertise and assistance. Although it may be challenging to gain market acceptance in these markets, we believe the assistance of such experts will expedite the process.

Our technology is advanced, not only for its scientific characteristics, but also for maneuverability, derived from the design and understanding of technical structures. Technology itself is spiritual.

~~2. Creating a creative business platform through independent design and development.~~

We intend to build a comprehensive platform, including blockchain technology, the Internet of Things, the health industry and the stock market. Once established, this platform will support UBI’s global operations.

~~3. Management believes it has a good network in the health industry in China.~~

In China, we believe the company’s management has a good network in the integration of the health industry, which can be used for scientific research and development, raw material production bases and other industrial chains. The company’s management is also familiar with the international pharmaceutical market and the food market.

~~Our management believes the Company’s management and consulting team, are the industry’s leading talent and professionals. They have a professional, quality, wisdom, and innovation.~~

At present, food and drug safety is a major challenge for human beings. Counterfeit food and drug products are very common in the Chinese market. These problems are derived from nature problems and human factors. The laws and regulations are not perfect and complete and law enforcement is not seriously implemented in many occasions. The occurrence of poison capsule events, vaccine cases, ginkgo leaf, licorice tablets and other major drug cases, seriously affecting people’s physical and mental health. Therefore, the safety of food and medicine is closely linked to the vital interests of hundreds of millions of people. So UBI’s market for food and drug safety goals is accurate and huge.

We plan to use application of information technology (IT), blockchain technology and IoT technology that permeate virtually all aspects of corporate and social activity, effective combination of food and drugs safety and management of labor relations. The products and services enabled by it have had a major impact to the healthcare industry. As we look to the future, emerging technologies raise new trend in security, law enforcement, privacy, safety in food and drug of healthcare industry.

~~In the future marketing~~Acquisition of UBI platform and products, we will mainly go through the Internet of Things to do online and offline store marketing. Marketing will also be promoted through cross-border e-commerce platforms. Conference marketing and professional channel marketing will be utilized. Our products and designs consider the overall needs of the population and will be tailor-made for some clients. We are currently paying attention to the development, formation and needs of “one belt, one road” markets.

Management believes Chinese consumers are more likely to consider buying a product if they see it mentioned on a social-media site and more likely to purchase a product or service if a friend or acquaintance recommends it on a social-media site.

~~The Company does not at this time engage in any manufacturing but may engage in manufacturing of products to be sold on the Company’s website in the future.~~

Shenzhen Cross Border E-commerce Co., formerly, Shenzhen Nova Cross-Border E-commerce, Ltd. (“UBI Shenzhen”)

On May 16, 2017, the Board of Directors of the Company ratified and approved an Acquisition Agreement ~~with Shenzhen Nova E-commerce, Ltd., (“NOVA”), a private Shenzhen Chinese corporation.~~between the Company and UBI Shenzhen. Under the terms of the Agreement, UBI acquired 100% ownership of ~~Nova~~UBI Shenzhen in exchange for the issuance to UBI Shenzhen’s shareholders of 25,000,000 shares of UBI unregistered restricted Class C common shares by UBI. With the NOVA ownership completed, the former 130 NOVA shareholders received UBI Class C common shares based on their pro-rata ownership of NOVA. With the NOVA acquisition completed and the namestock. Upon completion of the ~~permit holder changed to~~acquisition, UBI ~~and NOVA~~Shenzhen became a 100% owned subsidiary of ~~the~~ UBI.

The shareholders of NOVA converted their ownership of NOVA to UBIA’s Class C common shares. Following the conversion, NOVA shares were canceled. In China, the conversion of shares requires the Chinese authorities to cancel NOVA’s registered shares. The takeover formally takes place when the government cancels NOVA shares. The Chinese government approved the acquisition as of August 29, 2017.

UBI Shenzhen ~~Nova E-commerce Ltd. (“NOVA”)~~ was ~~incorporated~~formed as a private Shenzhen Chinese company on May 26, 2016, under the name Nova Cross-Border E-Commerce, and ~~currently~~ operates an online store in China selling a wide range of products including maternal and infant products, cosmetics, wine, household goods, digital and luxury ~~products. Nova’s~~products via its Oya Mall, a cross-border e-commerce platform. This website ~~became operational~~entered into operation in April, 2017.

~~Nova’s~~In April 2018, UBI Shenzhen changed its name from Shenzhen Nova Cross-Border E-commerce, Ltd. to UBI Shenzhen Cross Border E-commerce Co. UBI Shenzhen is registered in Qianhai Free Trade Zone, China. The website changed its name from www.oyamall.com to www.hihealth8.com in April 2018. On September 1, 2018, the website became operational as a marketplace for customers can buy products including, food, non-prescription medicine, skin care products, etc.

UBI Shenzhen’s operations ~~prior to the date of acquisition, included,~~include, but ~~was~~are not limited to:

NOVA is registered in Qianhai Free Trade Zone, China. Its business operation is an e-commerce platform offering online retail service, via OYA Mall. From its inception on May 26, 2016 through April 2017, NOVA has been building its website and infrastructure. Nova has commenced its pilot operation in May 2017.Overview

~~NOVA’s original Chinese language website experienced~~UBI Blockchain Internet is a ~~number~~company focused on research & development and application of ~~technical problems, especially dealing with Chinese currency. Management decided it would be more cost effective~~blockchain technology, including the combination of Internet of Things (“IoT”) and other high-tech technologies to establish a new website under the domain name. www.hihealth8.com. The website will allow people with Chinese currency who have a local Chinese bank account to purchase products through this website, where customers will be able to purchase products, including food, non-prescription medicine, skin care products etc. offered on the website. For the purpose of this Quarterly Report, the website is not part of this Report, but referenced for informational purposes.

~~Nova employs two people principally involved~~health industry issues prevalent in ~~website related creation/maintenance activities. Nova’s expenses are being funded by loan from Tony Liu.~~China.

~~Recent Events~~UBI’s business focus on blockchain technology is based on management’s persistent exploration and pursuit of solutions to prevent and eliminate the health industry issues prevalent in China, i.e. the safety issues of products and services caused by counterfeits and inferior substitutes resulting in harm to human lives. Entering the 21^st century, with the rise of technology innovation and progress, especially with the emergence of the blockchain technology, our management determined that an opportunity was available to discover and apply blockchain based solutions to the problem of safety and counterfeits in health products and services.

~~On January 5, 2018, the Securities and Exchange Commission announced the temporary suspension, pursuant to Section 12(k) of the Securities Exchange Act of 1934 (the “Exchange Act”), of trading~~UBI has established a dedicated R&D team, developed in the securities of UBI Blockchain Internet, Ltd. at 9:30 a.m. EST on January 8, 2018, and terminating at 11:59 p.m. EST, on January 22, 2018. The Commission temporarily suspended trading in the securities of UBIA because of (i) questions regarding the accuracy of assertions, since at least September 2017, by UBIA in filingscooperation with the Commission regarding the company’s business operations; and (ii) concerns about recent, unusual and unexplained market activity in the company’s Class A common stock since at least November 2017.

~~The suspension of trading eliminated our market makers and resulted in the listing of our stock on the grey sheets of the OTC markets. Prior to the suspension, our stock was listed on the OTC-QB.Broker-dealers are not willing or able to publicly quote grey sheets securities because of a lack of investor interest, company information availability or regulatory compliance.~~ Grey sheet is an unsolicited market where securities do not have bid or ask quotations. The listing on grey sheets makes our stock more difficult to trade, dramatically reduces the liquidity of our stock and has a negative impact on our investors. As such, our common stock is now on the grey sheets, this adversely effects the liquidity of the shares of common stock. Investors may be unable to liquidate their investment.

~~On January 10, 2018, the Company announced that~~ the Hong Kong ~~Special Administrative Region (“HKSAR”) approved in principle a grant of up to HK 3,018,750 (approximately $385,000) to assist in financing a~~Polytechnic University (HKPU), and has obtained approval from the Hong Kong government for the blockchain project, ~~entitled~~titled “Blockchain-Based Food and Drug Counterfeit Detection and Regulatory System” ~~(“the HKPU Project”)~~, coded as “UIM/331”. Information related to ~~be jointly developed by UBI~~this project is publicly available on Hong Kong Special Administration Region (“HKSAR”)’s official website at http://itf.gov.hk/l-eng/Prj-eng/Prj_Search_Index.asp. At the same time, UBI cooperates with blockchain experts and ~~The~~technical teams from Germany, India and other countries and regions, committed to the development of blockchain and its application in health industry.

On August 15-16, 2018, UBI together with other founders and sponsors, organized a Global Blockchain Cooperation Alliance Forum at the Company’s Hong Kong ~~Polytechnic University (“HKPU”). The related agreement also provides for~~Cyberport headquarters. More than 200 people who are blockchain experts, scholars, lawyers, financiers and entrepreneurs, from universities, research institutes, and media from over 20 countries and regions attended the event. UBI ~~Hong Kong to contribute up to HK $3,018,750 (approximately $385,000) to~~introduced and demonstrated the project cost in installments with the first installment of HK$561,198 (approximately $72,000) due upon HKSAR’s signing of the agreement (which occurred on January 5, 2018). The project is expected to be completed by November 14, 2019. In a series of two payments made by UBI Hong Kong on January 12, 2018, and January 16, 2018, UBI Hong Kong paid its first installment of a total of HK $561,198 (approximately $71,000) to HKPU. On February 1, 2018, HKSAR paid its first installment of HK $561,198 (approximately $71,000) to HKPU.

~~The agreement also provides for UBI Hong Kong to pay the remaining HK $2,457,552 (approximately $314,000)~~results of its ~~installments~~blockchain development and application at the conference, and proposed the concept “2018, the genesis of applied blockchain technology.”

UBI is optimistic about blockchain technology because blockchain is an innovative form of combination of computer skills such as ~~follows: HK$687,934 (approximately $88,000)~~distributed data storage, point-to-point transmission, consistent mechanisms, and encryption algorithms. Owing to its unique characteristics such as being traceable and modification resistant, decentralized and open transparent. Blockchain technology can be used to effectively address the safety and quality issues of products and services in the health industry. Monitored by ~~April 1, 2018; HK $687,934 (approximately $88,000) by October 1, 2018; HK $687,934 (approximately $88,000) by April 1, 2019~~the technology, the factitious factors are eliminated. The integration of Internet of Things “IoT”, Virtual Reality “VR”, Augmented Reality “AR”, Artificial Intelligence “AI”, and ~~HK$393,750 (approximately $50,000) within three months of~~other technologies will greatly improve the ~~completion of the HKPU Project. To date, UBI Hong Kong has not yet paid the HK $687,984 (approximately $88,000) installment due April 1, 2018.~~application level and effectiveness.

The ~~agreement also provides~~UBI blockchain system is based on the Ethereum framework and adopts the consortium blockchain (as defined below). This is the first generation and the first product of UBI as well. In early September 2018, the product was introduced to the market for promotion. UBI defines the consortium blockchain as follows: 1. Important product quality data must be stored in the blockchain to ensure its traceability and resistance to modification; 2. Only authorized organizations or individual are allowed to enter product data in the blockchain (characteristics of private chain); 3. Block Data in the blockchain is completely open and accessible to the public (characteristics of public chain). 4. Smart contracts are widely used in application scenarios.

UBI has developed a plan dedicated to the long-term development and application of blockchain technology to the Chinese health care industry. The Company’s goal is to reshape the trust system and innovate the business model for the ~~HKSAR~~Chinese health care industry by building the UBI blockchain based Global Health Chain system. This goal has three important parts: the first one is Kang-Chain Network, which will be an internet-based blockchain network capable of worldwide coverage, which we believe will enable connections through the internet between natural persons, medical institutions, and providers of health products and health services. We may also describe it as a value oriented or trust internet, to ~~pay~~differentiate it from the ~~remaining HK $2,457,522 (approximately $314,000)~~current information internet. A trust system, service concept, and value orientation can be built for the safeguard of ~~its installments periodically within 30 days after~~human lives and health quality from the ~~acceptance by~~perspective of super technology and cutting-edge thinking. We believe this future model for health differentiates itself from the ~~Commissioner~~current health practice in that it is built on trust and safeguard to provide a professional, targeted, flexible, easy to use, peer to peer, group to group, and safe health world that is writable and readable. We believe that the Kang-Chain Network will connect everyone, regardless the location in the world, to have all one’s needs of ~~Innovation and Technology (“CIT”), an agency~~health satisfied. We believe that the Kang-Chain Network has the potential to entirely change the health world as it is known to us today. The second part consists of the ~~HKSAR,~~Kang-Kang-Chain Cloud, which will fundamentally change people’s fear for and concerns about “clouds”. What is more important is that it will protect data privacy with clustered blockchain technology, so as to truly realize the data safety, privacy, permit based share, value, and socialization. Disconnected, and fragmented health data can be active and integrated with a humane premise, hence making it possible a human shared wealth to serve the human health. Kang Chain Cloud establishes a convenient cloud storage, a private safe, and information exchange of ~~certain Progress Reports~~health data and information for individuals. The third part is Kang-Chain Community. Exchange and transactions between people used to be ~~submitted periodically~~simple. However, along with the emergence of residual value, the trust between people started to disappear. People have worked hard to find a mechanism to get the lost trust back. People did not realize that the mechanism they were looking for had deviated from their original intention until today. Peer to peer is forthright and simple. This is exactly one of the essential characteristics of the blockchain technology, and the one that makes the disruption of reality and return to the nature possible. UBI believes the peer to peer business model will replace the current ones, and will work as a catalyst for the new communities and new business models. This also reflects the social progress and development, as well as the new normal of the shared demand, shared value, shared interest, and mutual reliance. The satisfaction between supply and demand featuring the exchange of peer to peer, group to group, and zero distance will naturally make the cost of exchange down to zero, value and speed maximized, and trusted. The innovative Kang Chain Community will be the highlight of the UBI global public health chain. Kang Chain Community is a commercial community formed out of an innovative model based on Kang Chain Network, and Kang Chain Cloud. This is a voluntary consumer community of the new era built on mutual understanding and trusting with their common needs and shared values.

Blockchain techniques have shown considerable adaptability in recent years, as various market sectors have sought to find ways of incorporating capabilities into their operations. Especially since 2014, the blockchain began to be applied in the industry and commerce, and the blockchain application has entered a new era in 2018. Previously, the blockchain was mainly applied in the cryptocurrency, which kind of replaced the blockchain to mainly serve the financial industry. However, as the governments of various countries strengthen the supervision of virtual currency, the cryptocurrency circle will be restricted, and the blockchain will play an increasingly important role in industrial applications. Blockchain technology will be widely applied in the future in the fields of finance, medical health, games, copyright, sharing economy, social contact, cloud computing and other fields or industries. It will subvert today’s thinking and social models in many ways.

Our management plans to focus its blockchain business on the health industry in China, and give priority to food and pharmaceuticals safety by ~~HKPU. The agreement provides~~providing effective technical systems, to prevent counterfeit foods and pharmaceuticals. With the development of blockchain technology, we can trace the entire process of food or pharmaceuticals in an all-round way in the integration of technology clusters such as IoT, VR, AR, AI, and robotics to provide manufacturers and consumers with the maximum symmetrical information exchange throughout the whole manufacturing and logistics process.

We are now in the early stages of blockchain technology, but we believe we have a good understanding of the framework design, the transition between the health industry language and the IT language, and the combination between the blockchain & the IoT and food & pharmaceutical technologies. We believe we are in a leading position and destined to have a bright future of blockchain technology.

Our management believes that ~~HKPU should provide CIT~~with the improvement of people’s living standards and the growing health awareness, the era of comprehensive health care has arrived. Following the article “Health China 2030” published by China government, we came to further understanding that healthcare, genetic testing, cell storage, precise health management, personal health data storage and analysis are increasingly recognized by humans and will become rigid demands. Traditional health care methods are being subverted. In 2015, “Health in China” was upgraded to China’s national strategy; in 2016, China launched the “Precision Medical Plan” with genetic testing technology as the main means; in 2016, “Health in China Outline 2030” plans to invest 60 billion yuan; in “The Development Plan for Emerging Industries of 2017”, genetic technology is included in National Document No. 1. In the United States, more than 5 million people receive genetic testing every year, creating a profit of 3 billion US dollars; Japan proposed the National Health Plan as early as in 1988 and nowadays the Japanese’s average life expectancy has reached 84 years old. Everybody needs health management. It is estimated that the market scale of China’s health industry will exceed 10 trillion yuan by 2020, according to China National Statistics Bureau.

Blockchain and the IoT are technologies that affect the future and are important ways and means to ensure the safety of health products and health services in the health market. UBI is the first ~~written Progress Report~~company to enter this market. Being the first one of applying blockchain technology in ~~a format acceptable to CIT covering from~~ the Commencement Date to August 31, 2018 to be submitted on or before September 30, 2018. While no written Progress Reports have yet been required or provided to CIT, periodic telephone conversations with CIT have occurred between CIT, HKPU,health industry will help the company position and develop itself in this field. The access in this market is of high criteria and cost. The ideas and beliefs of the ~~Company from time to time concerning HKPU Project’s progress. The agreement imposes no penalties on~~ UBI ~~Hong Kong should it fail to~~team make ~~any of its installment contributions except that HKSAR principally has~~us optimistic about the ~~right to cease their installment contributions if UBI Hong Kong fails to make its installment contributions.~~future.

In ~~February 2018, UBI Hong Kong performed a test at~~conclusion, we believe that the ~~offices of Guangxi Houde Mega Health Enterprise (“Guangxi”), a medical products company, of~~global health market has the ~~e-commerce “alpha” platform (using simulated test data provided by Guangxi). The test identified some technical issues that need~~potential to be ~~addressed; a second test~~huge, not only because it has ~~been scheduled for June, 2018.~~

~~Once a working model~~tremendous market dividends formed by resources that people continuously invest, but also because this market is related to human life and wellness, directly affecting the quality of ~~a platform is successfully operational,~~human life and happiness. Therefore, we will seize the ~~Company intends to sell~~emerging technology of blockchain and the ~~software to larger food and drug third party customers.~~

~~The agreement provides that the equipment acquired~~market opportunities at this particular stage, from the ~~HKPU Project will belong to HKPU, who is also identified as the Beneficiary~~perspective of ~~the grant for the project and is required to provide CIT with interim and a final accounting for the proceeds of the grant~~interests as well as ~~monies advanced by UBI Hong Kong whether~~ the project is successful or not. While HKPU, as the Beneficiary, is provided discretion on how income arising from the intellectual property rights from the Project Materials (including among other things computer software/programs, technical materials, models, documentsresponsibility for human life and materials compiled developed, produced or created by or on behalf of the Beneficiary – the “platform.” and Project Result is to be allocated, UBI Hong Kong is the sole and absolute beneficial owner (has title to) of all of the intellectual property rights which would include the platform if successfully completed under the project. However, there is no written agreement between UBI Delaware and UBI Hong Hong that provideswellness, striving for ~~title to the platform being conveyed to UBI Delaware.~~

The agreement also has provision whereby the HKSAR can terminate the grant under certain conditions. These conditions include, among other things, ethical misuse of funds received under the grant or violations of other requirements under the grant. This would include UBI Hong Kong’s failure to meet its general financial obligations as due or go into liquidation. In the event of termination, the HKSAR has the right to suspend payment under the grant or require that amounts previously paid by it be refundable under the grant.

~~The Company expects to use the technology learned from the HKPU Project to help it develop and market a platform system for application to control and manage~~ the safety of food and ~~drugs. Pursuant~~pharmaceuticals and the safety of health services.

UBI will firmly and persistently dedicate itself in research, development, application and promotion of the blockchain technology to ~~an understanding~~the health industry in China. We believe that this disruptive technology will profoundly affect the next ten years or even longer and will, in our opinion, benefit all humanity in the health industry. Our mission is to reshape the trust system and innovate the business model with blockchain technology. We will promote the wide application of blockchain technology in the entity industry and commerce, to explore further of the blockchain beyond its characteristics of value transfer.

Our growth strategy depends to a large extent on our ability to bring the products and technical service to potential customers in target markets. We plan to initially target the China market and gradually expand to Europe, the United States and the other countries and regions.

In order to achieve the company’s strategy, UBI has made a market development plan:

In its early stage of development, UBI has been cooperating with Hong Kong ~~the Company is responsible for the installments due~~Polytechnic University (HKPU) and ~~other costs relating to the HKPU Project paid by UBI Hong Kong. These costs are expected to be paid by UBI Hong Kong from loans~~ received support from the ~~Company’s CEO Tony Liu. The Company expects to record these costs as~~HKSAR. In this context, a joint effort in research and development ~~expenses~~participated by enterprises, universities and ~~increases in amounts due~~governments was formed with a competitive advantage. At the same time, we work closely with international blockchain experts and technical teams. We have brought together the advantages of technology and talent.

2. Innovate blockchain application system and products through independent design and development.

The initial design of our blockchain system has firmly grasped the food and drug safety issue, an industry pain point that are widely concerned. The technicians and enterprise personnel cooperated to ~~Tony Liu until such time as a “technologically feasible” working model~~make analysis and design, optimize various frameworks and solutions from the perspective of the ~~platform~~industry chain and supply chain, and has ~~been successfully produced.~~created a unique blockchain traceability system for safety purpose — consortium blockchain product. Meanwhile, we are deploying the UBI global health chain global system based on UBI blockchain technology world widely, in order to create Kang-Chain product group.

In China, UBI’s management has rich experience and resources in the health industry, which can be used for scientific research and development, raw material production bases and other industrial chains. The company’s management is also familiar with the international pharmaceutical market and the food market.

Our management, technical team and consulting team are the leading talents and professionals in their fields. They pursue high quality work. They are smart, responsible, charitable and gifted with vision and innovation spirit.

Our current target market is China, where we believe food and pharmaceuticals safety has become a major challenge. Counterfeit food and pharmaceuticals are very common in China, due to natural and man-made factors. Although the safety of food and pharmaceuticals is closely linked to the vital wellness of hundreds of millions of people, we believe that the laws and regulations governing food and pharmaceutical safety in China are not perfect or complete and may not be strictly enforced in many occasions. The occurrence of poison capsule events, vaccine incident, ginkgo leaf, licorice tablets and other major drug dealing and counterfeiting cases, have had serious affects on people’s physical and mental health.

UBI plans to develop a series of blockchain technology based products, such as private blockchain, consortium blockchain and public blockchain which are developed based on different application scenarios and market demands, and as well as the technical system platform. The company generates revenue and profits by providing services and effective products to potential target customers. The price will be determined by the market supply and demand. After initial promotion and marketing, the company’s products and services may have an impact on the existing healthcare industry. Looking ahead, emerging technologies will lead new trends in the health care industry, law enforcement, privacy protection, food and pharmaceuticals safety. UBI will produce good profit by providing specific blockchain solutions and systematic services.

In the future, we will mainly market UBI blockchain system and products through online and offline store. Marketing will also be promoted through cross-border e-commerce platforms. Conference marketing and professional channel marketing will be utilized. Our products and designs also consider the overall needs of human beings and will be tailor-made for some clients. Currently, we are paying attention to the development, formation and demands of China’s “One Belt, One Road” infrastructure initiative.

UBI management believe that UBI’s Global Health Public Blockchain will be our flagship product. On this public blockchain, we not only provide services for health institutions, enterprises, hospitals, etc., but more importantly, our health public blockchain network will connect various communities. In this case, peer-to-peer non-centralized marketing will be realized, which will make marketing faster and lower in cost. Meanwhile, enterprises and consumers can establish a common value on consuming. It will also enable individuals in the community to establish their own health data leger on the public chain, so they can effectively and safely manage their own health data, and become the true manager of their own health. Health data can be used for individuals to improve their own health, and can also be managed to create economic and social benefits through data analysis and appropriate use based on consented and shared value built among community members.

The Company does not now engage in any manufacturing but may engage in manufacturing of products to be sold on the Company’s website in the future.

We are or may become subject to a variety of laws and regulations in the State of Delaware, where we are incorporated, the United States and the People’s Republic of China (“PRC”) that involve matters central to our business, including laws and regulations regarding privacy, data protection, data security, data retention, consumer protection, advertising, electronic commerce, intellectual property, manufacturing, anti-bribery and anti-corruption, and economic or other trade prohibitions or sanctions. These laws and regulations are continuously evolving and developing. The scope and interpretation of the laws that are or may be applicable to us are often uncertain and may be conflicting, particularly with respect to foreign laws.

In particular, there are numerous U.S. federal, state, and local laws and regulations and foreign laws and regulations regarding privacy and the collection, sharing, use, processing, disclosure, and protection of personal information and other user data, the scope of which is changing, subject to differing interpretations, and may be inconsistent among different jurisdictions. We strive to comply with all applicable laws, policies, legal obligations, and industry codes of conduct relating to privacy, data security, and data protection. However, given that the scope, interpretation, and application of these laws and regulations are often uncertain and may be conflicting, it is possible that these obligations may be interpreted and applied in a manner that is inconsistent from one jurisdiction to another and may conflict with other rules or our practices. Any failure or perceived failure to comply with our privacy or security policies or privacy-related legal obligations by us or third-party service-providers or the failure or perceived failure by third-party apps, with which our users choose to share their data, to comply with their privacy policies or privacy-related legal obligations as they relate to the data shared with them, or any compromise of security that results in the unauthorized release or transfer of personally identifiable information or other user data, may result in governmental enforcement actions, litigation, or negative publicity, and could have an adverse effect on our brand and operating results.

We plan to develop solutions to ensure that data transfers from the E.U. provide adequate protections to comply with the E.U. Data Protection Directive. If we fail to develop such alternative data transfer solutions, one or more national data protection authorities in the European Union could bring enforcement actions seeking to prohibit or suspend our data transfers to the U.S. and we could also face additional legal liability, fines, negative publicity, and resulting loss of business.

Governments are continuing to focus on privacy and data security and it is possible that new privacy or data security laws will be passed or existing laws will be amended in a way that is material to our business. Any significant change to applicable laws, regulations, or industry practices regarding our users’ data could require us to modify our services and features, possibly in a material manner, and may limit our ability to develop new products, services, and features. Although we have made efforts to design our policies, procedures, and systems to comply with the current requirements of applicable state, federal, and foreign laws, changes to applicable laws and regulations in this area could subject us to additional regulation and oversight, any of which could significantly increase our operating costs.

The labeling, distribution, importation, marketing, and sale of our intended products are subject to extensive regulation by various U.S. state and federal and foreign agencies, including the CPSC, Federal Trade Commission, Food and Drug Administration, or FDA, Federal Communications Commission, and state attorneys general, as well as by various other federal, state, provincial, local, and international regulatory authorities in the countries in which our intended products and services are distributed or sold. If we fail to comply with any of these regulations, we could become subject to enforcement actions or the imposition of significant monetary fines, other penalties, or claims, which could harm our operating results or our ability to conduct our business.

The global nature of our business operations also create various domestic and foreign regulatory challenges and subject us to laws and regulations such as the U.S. Foreign Corrupt Practices Act, or FCPA, the U.K. Bribery Act, and similar anti-bribery and anti-corruption laws in other jurisdictions, and our intended products are also subject to U.S. export controls, including the U.S. Department of Commerce’s Export Administration Regulations and various economic and trade sanctions regulations established by the Treasury Department’s Office of Foreign Assets Controls. If we become liable under these laws or regulations, we may be forced to implement new measures to reduce our exposure to this liability. This may require us to expend substantial resources or to discontinue certain products or services, which would negatively affect our business, financial condition, and operating results. In addition, the increased attention focused upon liability issues as a result of lawsuits, regulatory proceedings, and legislative proposals could harm our brand or otherwise impact the growth of our business. Any costs incurred as a result of compliance or other liabilities under these laws or regulations could harm our business and operating results.

Because our business and employees are located in the PRC, our business is also regulated by the national and local laws of the PRC. We believe our conduct of business complies with existing PRC laws, rules and regulations.

We believe we are in material compliance with all applicable labor and safety laws and regulations in the PRC, including the PRC Labor Contract Law, the PRC Production Safety Law, the PRC Regulation for Insurance for Labor Injury, the PRC Unemployment Insurance Law, the PRC Provisional Insurance Measures for Maternity of Employees, PRC Interim Provisions on Registration of Social Insurance, PRC Interim Regulation on the Collection and Payment of Social Insurance Premiums and other related regulations, rules and provisions issued by the relevant governmental authorities from time to time.

According to the PRC Labor Contract Law, we are required to enter into labor contracts with our employees. We are required to pay no less than local minimum wages to our employees. We are also required to provide employees with labor safety and sanitation conditions meeting PRC government laws and regulations and carry out regular health examinations of our employees engaged in hazardous occupations. Violations of the PRC Labor Contract Law and the PRC Labor Law may result in the imposition of fines and other administrative and criminal liability in the case of serious violations. In addition, according to the PRC Social Insurance Law, employers like our PRC subsidiaries in China must provide employees with welfare schemes covering pension insurance, unemployment insurance, maternity insurance, work-related injury insurance, medical insurance, and housing funds.

The principal regulation governing foreign currency exchange in China is the Foreign Currency Administration Rules (1996), as amended (2008). Under these Rules, RMB is freely convertible for current account items, such as trade and service-related foreign exchange transactions, but not for capital account items, such as direct investment, loan or investment in securities outside China unless the prior approval of, and/or registration with, the State Administration of Foreign Exchange of the People’s Republic of China, or SAFE, or its local counterparts (as the case may be) is obtained.

Pursuant to the Foreign Currency Administration Rules, foreign invested enterprises, or FIEs, in China may purchase foreign currency without the approval of SAFE for trade and service-related foreign exchange transactions by providing commercial documents evidencing these transactions. They may also retain foreign exchange (subject to a cap approved by SAFE) to satisfy foreign exchange liabilities or to pay dividends. In addition, if a foreign company acquires a subsidiary in China, the acquired company will also become an FIE. However, the relevant PRC government authorities may limit or eliminate the ability of FIEs to purchase and retain foreign currencies in the future. In addition, foreign exchange transactions for direct investment, loan and investment in securities outside China are still subject to limitations and require approvals from, and/or registration with, SAFE.

We have 18 full-time employees and we engage the services 4447 non-employee contractors. Within our workforce, 8 employees are engaged in product and business development and 10 employees are engaged in ~~business development,~~ finance, human resources, facilities, information technology and general management and administration. We have no collective bargaining agreements with our employees and we have not experienced any work stoppages. We consider our relationship with our employees to be good.

The Company owns no real property. Our administrative offices are located at: SmartSpace 3F, Level 9, Unit 908, 100 Cyberport Rd., Hong Kong, People’s Republic of China., telephone: (212) 372-8836. The Company has been using this Hong Kong office space provided by UBI Hong Kong at a cost to the Company equal to UBI Hong Kong’s monthly rent of 22,100 Hong Kong Dollars (approximately $2,825 at the November 30, 2018 exchange rate). UBI Hong Kong owns 30,000,000 shares of the Company’s Class A common stock, 6,000,000 shares of the Company’s Class B common stock; and 40,000,000 shares of the Company’s C common stock.

Three Months Ended ~~February 28,~~November 30, 2018 Compared to Three Months Ended ~~February 28,~~November 30, 2017

During the three-month ~~periods~~period ended ~~February 28,~~November 30, 2018, the Company recognized $112,445 revenue from development agreements and ~~2017,~~ the Company had no ~~revenues.~~revenues in 2017.

For the three months ended ~~February 28,~~November 30, 2018, the Company had total operating expenses of ~~$655,074~~$553,923 as compared to ~~$426,122~~$1,223,524 for the same period in ~~2017.~~2017, a decrease of $669,601, or 55%. For the three months ended ~~February 28,~~November 30, 2018, operating expenses consisted of employee compensation of ~~$196,093~~$173,552 (including stock-based compensation of ~~$24,167)~~$0), consulting fees of ~~$305,883~~$185,000 (stock-based compensation of ~~$300,833)~~$185,000), ~~depreciation of $2,205,~~ professional fees of ~~$49,000,~~$68,620, occupancy ~~cost~~expense of ~~$23,069, research and development expenditure of $71,779~~$32,653, and other operating expenses of ~~$7,045.~~$94,098. For the three months ended ~~February 28,~~November 30, 2017, the Company’s operating expenses consisted of: of employee compensation of ~~$179,569~~$263,963 (including stock-based compensation of ~~$48,333)~~$72,500), consulting fees of ~~$231,667,~~$532,500, which was stock-based compensation, professional ~~fees~~fee of ~~$8,147~~$343,872 (stock-based compensation of $335,872), occupancy expense of $16,621 and other operating expenses of ~~$6,739.~~$66,568. The ~~increase~~decrease in operating expenses resulted from the ~~Company’s effort~~decreases in employee compensation, consulting fees, and professional fees due to ~~develop Blockchain technology-based applications.~~

~~In January 2018,~~lower stock-based compensation, offset by the ~~Company through UBI Hong Kong paid $71,779 to the HKPU Project. The Company charged this payment as research~~increases in occupancy expense and ~~development~~other operating expenses. ~~The Company will continue to charge future HKPU Project payments as R&D expense until such time as a “technologically feasible” working model of the platform has been successfully produced.~~

For the three months ended ~~February 28,~~November 30, 2018, the interest expense accrued ~~on loans~~for loan from Tony Liu was ~~$18,019.~~

~~For~~$34,781, an increase of $23,955, compared to $10,826 in the three months ended ~~February 28, 2017, the Company had a gain of $47,003 from settlement of accounts payable and accrued liabilities.~~November 30, 2017.

For the three months ended ~~February 28,~~November 30, 2018, the Company had a net loss of ~~$673,161~~$476,458 or $(0.00) per share of Class A and Class C common stock and compared to a loss of $1,234,340 or $(0.01) per share of Class A ~~Class B and Class C common stock compared to a loss of $379,119 or $(0.01) per share of Class A, Class B and Class C common stock for the same period last year.~~

~~Six Months Ended February 28, 2018 Compared to Six Months Ended February 28, 2017~~

~~During the six-month periods ended February 28, 2018 and 2017, the Company had no revenues.~~

For the six months ended February 28, 2018, the Company had total operating expenses of $1,878,598 as compared to $501,991 in 2017. For the six months ended February 28, 2018, operating expenses consisted of employee compensation of $460,056 (including stock-based compensation of $96,668), consulting fees of $838,383 (stock-based compensation of $833,334), depreciation of $4,324, professional fees of $392,872 (stock-based compensation of $335,872), occupancy cost of $39,690, research and development expenditure of $71,779 and other operating expenses of $71,494. For the six months ended February 28, 2017, the Company’s operating expenses consisted of: of employee compensation of $179,569 (including stock-based compensation of $48,333), consulting fees of $256,667 (stock-based compensation of $231,667), professional fees of $39,516 and other operating expenses of $26,239. The increase in operating expenses resulted from the Company’s effort to develop Blockchain technology-based applications.

In January 2018, the Company through UBI Hong Kong paid $71,779 to the HKPU Project. The Company charged this payment as research and development expenses. The Company will continue to charge future HKPU Project payments as R&D expense until such time as a “technologically feasible” working model of the platform has been successfully produced.

~~For the six months ended February 28, 2018, the interest expense accrued on loans from Tony Liu was $28,845.~~

~~For the six months ended February 28, 2017, the Company had a gain of $47,003 from settlement of accounts payable and accrued liabilities and a gain of $572 from settlement of bank overdraft.~~

For the six months ended February 28, 2018, the Company had a net loss of $1,907,501 or $(0.02) per share of Class A, Class B, and Class C common stock compared to a loss of $454,416 or ($0.02) per share of Class A, Class B and Class C common stock for the same period last year.

At ~~February 28,~~November 30, 2018, the Company had cash of ~~$59,523~~$189,323 and current liabilities of ~~$1,337,836.~~$2,525,753. For the ~~six~~three months ended ~~February 28,~~November 30, 2018, the Company incurred a net loss of ~~$1,907,501.~~$476,458. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.

The Company’s ability to continue as a going concern is contingent upon the successful completion of additional financing arrangements and its ability to achieve and maintain profitable operations. Management plans to raise equity capital to finance the operating and capital requirements of the Company. Amounts raised will be used to further development of the Company’s services, to provide financing for marketing and promotion and for other working capital purposes. While the Company is putting forth its best efforts to achieve the above plans, there is no assurance that any such activity will generate funds that will be available for operations.

These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Our financial statements do not include any adjustments that might arise from this uncertainty.

As of ~~February 28,~~November 30, 2018, the Company has total assets of ~~$1,091,926~~$671,113 consisting of cash ~~$59,523,~~$189,323, inventory of ~~$28,153,~~$23,083, prepaid stock-based compensation of ~~$863,333,~~$308,333, deposit and prepaid ~~expenses~~expense of ~~$26,946,~~$25,651, office equipment of ~~$18,136~~$7,170 and capitalized website development costs of ~~$95,835 and total~~$117,553. Total liabilities is $2,525,753 as of ~~$1,337,836.~~November 30, 2018.

The Company started to generate limited income from project development during the quarter ended November 30, 2018. The working capital was provided by a major shareholder of the Company. The Company has limited financial resources available, which has had an adverse impact on the Company’s liquidity, activities and operations. These limitations have adversely affected the Company’s ability to obtain certain projects and pursue additional business. Without realization of additional capital, it would be unlikely for the Company to continue as a going concern. In order for the Company to remain a Going Concern it will need to find additional capital. Additional working capital may be sought through additional debt or equity private placements, additional notes payable to banks or related parties (officers, directors or stockholders), or from other available funding sources at market rates of interest, or a combination of these. The ability to raise necessary financing will depend on many factors, including the nature and prospects of any business to be acquired and the economic and market conditions prevailing at the time financing is sought. No assurances can be given that any necessary financing can be obtained on terms favorable to the Company, or at all.

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results or operations, liquidity, capital expenditures or capital resources that is material to investors.

Revenue Recognition: We recognize revenue from services and product sales once all of the following criteria for revenue recognition have been met: pervasive evidence that an agreement exists; the services have been rendered; the fee is fixed and determinable and not subject to refund or adjustment; and collection of the amount due is reasonable assured. ~~For the periods presented, the Company had no revenues.~~

Management has evaluated recently issued accounting pronouncements through ~~February 28,~~November 30, 2018 and concluded that they will not have a material effect on future financial statements.

Our disclosure controls and procedures, as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in rules and forms adopted by the SEC, and that such information is accumulated and communicated to management, including the Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosures.

Management, with the participation of the Chief Executive Officer and the Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures as of the end of the quarterly period covered by this report. Based on such evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that, our disclosure controls and procedures were ~~not~~ effective. Our disclosure controls and procedures were not effective because of the “material weaknesses” described below under “Management’s report on internal control over financial reporting,” which are in the process of being remediated as described below under “Management Plan to Remediate Material Weaknesses.”

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting, as defined in rules promulgated under the Exchange Act, is a process designed by, or under the supervision of, our Chief Executive Officer and Chief Financial Officer and affected by our Board of Directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. Internal control over financial reporting includes those policies and procedures that:

Because of its inherent limitations, a system of internal control over financial reporting can provide only reasonable, not absolute, assurance that the objectives of the control system are met and may not prevent or detect misstatements. Internal control over financial reporting is a process that involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion or improper override. Because of such limitations, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process, and it is possible to design into the process safeguards to reduce, though not eliminate, this risk. Further, over time control may become inadequate because of changes in conditions or the degree of compliance with the policies or procedures may deteriorate.

Our management assessed the effectiveness of our internal control over financial reporting as of February 28, 2018. In making its assessment, management used the criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). Based on its assessment, management has concluded that we had certain control deficiencies described below that constituted material weaknesses in our internal controls over financial reporting. As a result, our internal control over financial reporting was not effective as of February 28, 2018.

A “material weakness” is defined under SEC rules as a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of a company’s annual or interim financial statements will not be prevented or detected on a timely basis by the company’s internal controls. As a result of management’s review of the investigation issues and results, and other internal reviews and evaluations that were completed after the end of quarter related to the preparation of management’s report on internal controls over financial reporting required for this quarterly report on Form 10-Q, management concluded that we had material weaknesses in our control environment and financial reporting process consisting of the following:

We do not believe the material weaknesses described above caused any meaningful or significant misreporting of our financial condition and results of operations for the quarter ended February 28, 2018. However, management believes that the lack of a functioning audit committee and the lack of a majority of outside directors on our board of directors results in ineffective oversight in the establishment and monitoring of required internal controls and procedures, which could result in a material misstatement in our financial statements in future periods.

Management is pursuing the implementation of corrective measures to address the material weaknesses described below. In an effort to remediate the identified material weaknesses and other deficiencies and enhance our internal controls, we have initiated, or plan to initiate, the following series of measures:

We will create a position to segregate duties consistent with control objectives and will increase our personnel resources and technical accounting expertise within the accounting function when funds are available to us. We plan to appoint one or more outside directors to our board of directors who shall be appointed to an audit committee resulting in a fully functioning audit committee who will undertake the oversight in the establishment and monitoring of required internal controls and procedures such as reviewing and approving estimates and assumptions made by management when funds are available to us.

We believe the remediation measures described above will remediate the material weaknesses we have identified and strengthen our internal control over financial reporting. We are committed to continuing to improve our internal control processes and will continue to diligently and vigorously review our financial reporting controls and procedures. As we continue to evaluate and work to improve our internal control over financial reporting, we may determine to take additional measures to address control deficiencies or determine to modify, or in appropriate circumstances not to complete, certain of the remediation measures described above.

There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the ~~most recent fiscal quarter~~quarterly period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.

We are not presently a party to any material litigation, nor to the knowledge of management is any litigation threatened against us, which may materially affect us.

See Risk Factors set forth in Part I, Item 1A of the Company’s Annual Report on 10-K for the fiscal year ended August 31, ~~2017~~2018 and the discussion in Item 2 of Part I above, under “Liquidity and Capital Resources.” ~~Additionally see Risk Factors set forth in the Form 10 Information disclosed in the Company’s Amended Current Report in Form 8-K/A filed in the Commission on November 17, 2017.~~

On October 2, 2017, the Board of Directors approved the issuance 82,000 unregistered restricted Class A common stock in exchange for legal services. We did not engage in any form of general solicitation or general advertising in connection with this transaction. The shareholders were provided access to all material information, which they requested and all information necessary to verify such information and was afforded access to our management in connection with this transaction. The shares of common stock issued contained a legend restricting transferability absent registration or applicable exemption. We relied upon Section 4(2) of the Securities Act for the offer and sale. We believed that Section 4(2) was available because the offer and sale did not involve a public offering and there was not general solicitation or general advertising involved in the offer or sale.

~~The 82,000 Class A were subsequently registered in a S-1 Registration Statement that became effective on December 22, 2017.~~None.

Item 4 — ~~Submission of Matters to a Vote of Security Holders~~Mine Safety Disclosures

The Company filed a Registration Statement on Form S-1, that registered 20,582,000 of our Class A Common Stock, par value $0.001, and 51,700,000 shares of our Class C Common Stock, par value $0.001. The Registration became effective on December 22, 2017. After the stock suspension Notice was issued, the Commission asked the Company to file a Post-Effective Amendment to disclose the stock suspension and its ramifications. The Company filed a Post-Effective Amendment NoNo. 1 on February 5, 2018, ~~and filed~~ Post-Effective Amendment NoNo. 2 on April 4, 2018, Post-Effective Amendment No. 3 on April 19, 2018, Post-Effective Amendment No. 4 on May 15, 2018, and Post-Effective Amendment No. 5 on July 2, 2018.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Large accelerated filer [ ]	Accelerated filer [ ]	Non-accelerated filer ~~[ ]~~[X]	Smaller reporting company [X]
			Emerging growth company [ ]

	Page
PART I - FINANCIAL INFORMATION	31
Item I. Financial Statements	31
Balance Sheets as of ~~February 28,~~November 30, 2018 (Unaudited) and August 31, ~~2017~~2018	31
Statements of Operations for the Three ~~and Six~~ Months Ended ~~February 28, 2018(Unaudited)~~November 30, 2018 (Unaudited)	42
Statements of Cash Flows for the ~~Six~~Three Months Ended ~~February 28,~~November 30, 2018 and ~~February 28,~~November 30, 2017 (Unaudited)	53
Notes to Financial Statements (Unaudited)	64
Item 2. - Management’s Discussion and Analysis of Financial Condition and Results of Operations	18
~~Results of Operations~~	31
Item 3. Quantitative and Qualitative Disclosures about Market Risk	3327
Item ~~4T.~~4. Controls and Procedures	3327
PART II. OTHER INFORMATION	3628
Item 1 — Legal Proceedings	3628
Item 1A -— Risk Factors	3628
Item 2 — Unregistered Sales of Equity Securities and Use of Proceeds	3628
Item 3 — Defaults Upon Senior Securities	3628
Item 4 — ~~Submission of Matters to a Vote of Security Holders~~Mine Safety Disclosures	3628
Item 5 — Other Information	3628
Item 6 –— Exhibits	3728
SIGNATURES	3829

	February 28, 2018			August 31, 2017			November 30, 2018			August 31, 2018
	(Unaudited)
Assets

Current Assets
Cash	$	59,523		$	15,406		$	189,323		$	23,434
Inventory		28,153			-			23,083			23,448
Current portion of prepaid stock-based salaries and consulting fees		740,000			1,300,000			308,333			493,333
Deposit and prepaid expenses		26,946			-			25,651			18,093
Total Current Assets		854,622			1,315,406			546,390			558,308

Office equipment, net of accumulated depreciation		18,136			17,950			7,170			9,359

Other Assets
Non-current portion of prepaid stock-based salaries and consulting fees		123,333			493,333			-			-
Website development costs		95,835			92,035
Intangible assets, net of accumulated amortization								117,553			127,037

Total Other Assets		219,168			585,368			117,553			127,037

Total Assets	$	1,091,926		$	1,918,724		$	671,113		$	694,704

Liabilities and Stockholders’ Equity (Deficit)

Current liabilities:

Accounts payable and accrued liabilities	$	90,258		$	71,425		$	160,032		$	151,405
Due to related party		1,247,578			514,081			2,365,721			1,923,599
Total current liabilities		1,337,836			585,506			2,525,753			2,075,004
Total liabilities		1,337,836			585,506			2,525,753			2,075,004

Stockholders’ Equity (Deficit):
Preferred Stock: $0.001 par value, 5,000,000 shares authorized, 0 and 0 shares issued and outstanding as of February 28, 2018 and August 31, 2017, respectively		-			-
Class A common stock, $0.001 par value, 1,000,000,000 shares authorized, 30,799,046 and 30,717,046 shares issued and outstanding as of February 28, 2018 and August 31, 2017, respectively		30,799			30,717
Class B common stock, $0.001 par value, 500,000,000 shares authorized, 6,000,000 and 6,000,000 shares issued and outstanding as of February 28, 2018 and August 31, 2017, respectively		6,000			6,000
Class C common stock, $0.001 par value, 500,000,000 shares authorized, 73,400,000 and 73,400,000 shares issued and outstanding as of February 28, 2018 and August 31, 2017, respectively		73,400			73,400
Preferred Stock: $0.001 par value, 5,000,000 shares authorized, 0 and 0 shares issued and outstanding as of November 30, 2018 and August 31, 2018, respectively								-			-
Class A common stock, $0.001 par value, 1,000,000,000 shares authorized, 30,799,046 and 30,799,046 shares issued and outstanding as of November 30, 2018 and August 31, 2018, respectively								30,799			30,799
Class B common stock, $0.001 par value, 500,000,000 shares authorized, 6,000,000 and 6,000,000 shares issued and outstanding as of November 30, 2018 and August 31, 2018, respectively								6,000			6,000
Class C common stock, $0.001 par value, 500,000,000 shares authorized, 73,550,000 and 73,550,000 shares issued and outstanding as of November 30, 2018 and August 31, 2018, respectively								73,550			73,550
Additional paid in capital		7,811,721			7,475,931			7,841,571			7,841,571
Stock subscription payable		90,521			90,521			90,521			90,521
Accumulated other comprehensive income		(7,424	)		75			27,169			25,051
Accumulated deficit		(8,250,927	)		(6,343,426	)		(9,924,250	)		(9,447,792	)
Total stockholders’ equity (deficit)		(245,910	)		1,333,218			(1,854,640	)		(1,380,300	)

Total liabilities and Stockholders’ Equity (Deficit)	$	1,091,926		$	1,918,724		$	671,113		$	694,704

	2018			2017

Revenue From Development Agreements	$	112,445		$	-

Operating Expenses:
Employee compensation (including stock-based compensation of $0 and $72,500, respectively)		173,552			263,963
Consulting fees (including stock-based compensation of $185,000 and $532,500, respectively		185,000			532,500
Professional fees (including stock-based compensation of $0 and $335,872, respectively)		68,620			343,872
Occupancy		32,653			16,621
Depreciation and amortization		9,644			2,119
Other		84,454			64,449
Total Operating Expenses		553,923			1,223,524

Loss from Operations		(441,478	)		(1,223,524	)

Other Income (Expenses)
Interest expense - related party		(34,781	)		(10,826	)
Interest income		14			-
Gain (loss) on foreign currency exchange		(213	)		10
Total Other Income (Expenses) - net		(34,980	)		(10,816	)

Net Loss		(476,458	)		(1,234,340	)

Other comprehensive income (loss):
Foreign exchange translation adjustment		2,118			(785	)
Comprehensive Loss	$	(474,340	)	$	(1,235,125	)

Net Loss per share of Class A, Class B, and Class C Common Stock
Basic and Diluted	$	(0.00	)	$	(0.01	)

Weighted Average Number of Class A, Class B, and Class C Common Shares
Basic and Diluted		110,349,046			110,214,181

	For the six months ended February 28, 2018			For the six months ended February 28, 2017			2018			2017
	(Unaudited)			(Unaudited)
Cash Flows from Operating Activities
Net Loss	$	(1,907,501	)	$	(454,416	)	$	(476,458	)	$	(1,234,340	)
Adjustments to reconcile net loss to net cash used by operating activities:
Depreciation expense		4,322			-
Depreciation and amortization expense								9,644			2,119
Stock-based compensation - employees		96,668			48,333			-			72,500
Stock-based compensation - consulting fees		833,334			231,667			185,000			532,500
Stock-based compensation - professional fees		335,872			-
Gain on settlement of bank overdraft		-			(572	)
Gain on settlement of accounts Payable and accrued liabilities					(47,003	)
Stock-based compensation professional fees								-			335,872
Changes in operating assets and liabilities:
Increase in inventory		(27,288	)
Increase in prepaid expense		(26,117	)		(6,000	)
Increase (decrease) in accounts payable and accrued liabilities		18,085			(1,285	)
Increase (decrease) in bank overdraft		-			(630	)
Increase in deposit and prepaid expenses								(7,884	)		(5,000	)
Increase in accounts payable and accrued liabilities								8,488			53,632
Increase in interest payable to related party		28,810			-			34,781			10,824
Net cash used by operating activities		(643,815	)		(229,906	)		(246,429	)		(231,893	)

Cash Flows from investing activities								-			-
Purchases of office equipment		(3,925	)		(6,363	)
Net cash used by operating activities		(3,925	)		(6,363	)

Cash Flows from financing activities
Repayments to former related party		-			(26,981	)
Due to related party		692,079			149,485
Repayment of note payable to former related party		-			(50,000	)
Buyback of preferred stock		-			(33,735	)
Proceeds from sale of common stock - net		-			180,000
Contributed capital		-			17,500
Loans from related party								413,054			279,540
Net cash provided by financing activities		692,079			236,269			413,054			279,540

Effect of exchange rate on cash		(222	)		-			(736	)		(47	)
Net Increase (Decrease) in Cash		44,117			-
Net Increase in Cash								165,889			47,600
Cash and cash equivalents at beginning of period		15,406			-			23,434			15,406
Cash and cash equivalents at end of period	$	59,523		$	-		$	189,323		$	63,006

Supplemental Cash Flow Information:
Income taxes paid	$	-		$	-		$	-		$	-
Interest paid	$	-		$	-		$	-		$	-
Non-cash Investing and Financing Activities:

(Mark one)

[X]	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	For the three months ended February 28, 2018			For the three months ended February 28, 2017			For the six months ended February 28, 2018			For the six months ended February 28, 2017
	(Unaudited)			(Unaudited)			(Unaudited)			(Unaudited)

Revenue	$	-		$	-		$	-		$	-

Operating Expenses:
Employee compensation (including stock-based compensation of $24,167 , $48,333, $96,668 and $48,333 respectively)		196,093			179,569			460,056			179,569
Consulting fees (including stock-based compensation of $300,833, $231,667, $833,334 and $231,667 respectively		305,883			231,667			838,383			256,667
Depreciation		2,205			-			4,324			-
Professional fees (including stock-based compensation of $0, $0, $335,872 and $0, respectively)		49,000			8,147			392,872			39,516
Occupancy		23,069			-			39,690			-
Research and development		71,779			-			71,779
Other		7,045			6,739			71,494			26,239
Total Operating Expenses		655,074			426,122			1,878,598			501,991

Loss from Operations		(655,074	)		(426,122	)		(1,878,598	)		(501,991	)

Other Income (Expenses)
Interest expense - related party		(18,019	)		-			(28,845	)		-
Gain (loss) on foreign currency exchange		(68	)		-			(58	)		-
Gain on settlement of accounts payable and accrued liabilities					47,003						47,003
Gain on settlement of bank overdraft		-			-			-			572
Total Other Income (Expenses) - net		(18,087	)		47,003			(28,903	)		47,575

Net Loss		(673,161	)		(379,119	)		(1,907,501	)		(454,416	)

Other comprehensive income (loss):
Foreign exchange translation adjustment		(6,714	)		-			(7,499	)		-
Comprehensive Loss	$	(679,875	)	$	(379,119	)	$	(1,915,000	)	$	(454,416	)

Net Loss per share of Class A, Class B, and Class C Common Stock
Basic and Diluted	$	(0.01	)	$	(0.01	)	$	(0.02	)	$	(0.02	)

Weighted Average Number of Class A, Class B, and Class C Common Shares
Basic and Diluted		110,199,046			36,217,046			110,185,002			24,250,195

Year ended February 28,	Amount
2019	$	19,167
2020		19,167
2021		19,167
2022		19,167
2023		19,167
Total	$	95,835

Cash	$	-
Office equipment, net		13,628
Website development costs		92,035
Total assets		105,663

Accounts payable and accrued liabilities		24,651
Due to related party		135,865
Total liabilities		160,516

Excess of liabilities over assets	$	54,853

	Three Months Ended February 28, 2017			Six Months Ended February 28, 2017
	(Unaudited)			(Unaudited)

Revenue	$	-		$	-

Operating expenses:
Employee compensation (including stock - based compensation of $48,333 and $48,333, respectively)		202,223			250,275
Consulting fees (including stock - based compensation of $231,667 and $231,667, respectively)		231,667			256,667
Professional fees		8,147			39,516
Marketing		7,751			138,209
Occupancy		38,708			81,072
Other		10,410			31,227
Total operating expenses		498,906			796,966
Loss from Operations		(498,906	)		(796,966	)
Other Income (expenses):
Gain on settlement of accounts payable and accrued liabilities		47,003			47,003
Gain on settlement of bank overdraft		-			572
Net Loss	$	(451,903	)	$	(749,391	)
Net Loss per share of Class A, Class B, and Class C common stock - basic and diluted	$	(0.01	)	$	(0.02	)
Weighted average number of Class A, Class B, and Class C Common Shares outstanding - basic and diluted		55,217,046			49,250,195

	Fair value of stock issuance (Note 6)		Prepaid balance at February 28, 2018			Prepaid balance at August 31, 2017			Fair value of stock issuance (Note 6)		Prepaid balance at November 30, 2018			Prepaid balance at August 31, 2018
1,450,000 shares of Class C common stock issued to 7 employees on April 3, 2017 pursuant to service agreements between UBI Delaware and the respective employees with a service term of one year expiring December 31, 2017	$	290,000	$	24,167		$	96,667		$	290,000	$	-		$	-
6,950,000 shares of Class C common stock issued to 38 consultants on April 3, 2017 pursuant to service agreements between UBI Delaware and the respective consultants with a service term of one year expiring December 31, 2017		1,390,000		115,833			463,333			1,390,000		-			-
500,000 shares of Class A common stock issued to a consultant on May 1, 2017 pursuant to Consulting Agreement dated April 28, 2017 between UI Delaware and the consultant with a service term of two years expiring April 30, 2019		1,480,000		1,048,333			1,233,333
500,000 shares of Class A common stock issued to a consultant on May 1, 2017 pursuant to Consulting Agreement dated April 28, 2017 between UBI Delaware and the respective consultant with a service term of two years expiring April 30, 2019										1,480,000		308,333			493,333
Total	$	3,160,000		1,188,333			1,793,333		$	3,160,000		308,333			493,333
Current portion				(880,000	)		(1,300,000	)				(308,333	)		(493,333	)
Non-current portion			$	308,333		$	493,333				$	-		$	-

Years ending	Amount
November 30, 2019	$	27,510
November 30, 2020		27,510
November 30, 2021		27,510
November 30, 2022		27,510
November 30, 2023		7,513
Total	$	117,553

Tax Jurisdiction	November 30, 2018		August 31, 2018
United States	$	1,351,000	$	1,296,000
Hong Kong		1,061,000		855,000
China (UBI Shenzhen)		762,000		732,000
Total	$	3,174,000	$	2,883,000

Year ended February 28, 2019	$	40,428
Year ended February 28, 2020		33,343
Year ended February 28, 2021		13,664
Total	$	87,435

Year ending November 30, 2019	$	34,246
Year ending November 30, 2020		17,780
Total	$	52,026

	●	Researching and developing business opportunities unique to a Chinese customer base

	●	Building corporate infrastructure and administration

	●	Integration of multiple technologies and programs

	●	Building Business Relationships

	●	Human resource staffing

	●	Training personnel

	●	Equipment procurement

	●	Building the corporate website

	●	Developing marketing strategies to capitalize on commercialization activities

	●	Establish and maintain strategic collaborations with product suppliers

	●	Obtain financing to implement the business activities

	●	By the end of 2018, the Company will further improve the development and promotion of the consortium blockchain product.

	●	Starting from 2019, the company will develop the “UBI Global Health Public Chain” with full efforts. Our strategic position and product deployment consists of “Kang-Chain Net”, “Kang-Chain Cloud” and “Kang-Chain Community” to create and provide comprehensive security services plan for human health. This plan is to be completed in three years.

	●	By the end of 2021, it will be fully promoted and applied.

	●	~~pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;~~

	●	provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and our Board of Directors; and

	●	~~provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.~~

	1)	lack of a functioning audit committee due to a lack of a majority of independent members and a lack of a majority of outside directors on our board of directors, resulting in ineffective oversight in the establishment and monitoring of required internal controls and procedures; and

	2)	~~insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of US GAAP and SEC disclosure requirements.~~

Exhibit Number	~~Ref~~	Description of Document
31.1		Certifications of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2		Certifications of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1		Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.

32.2		Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.

101	*	The following materials from this Quarterly Report on Form 10-Q for the quarter ended ~~February 28,~~May 31, 2018, formatted in XBRL (eXtensible Business Reporting Language):

		(1) Balance Sheets at ~~February 28,~~November 30, 2018 (Unaudited) and August 31, 2017 (Audited).

		(2) Unaudited Statements of Operations for the three ~~and six-month~~month periods ended ~~February 28,~~November 30, 2018 and 2017.

		(3) Unaudited Statements of Cash Flows for the ~~six-month~~three month periods ended ~~February 28,~~November 30, 2018 and 2017.

		(4) Notes to the financial statements (Unaudited).

	UBI Blockchain Internet, Ltd. Registrant

Date: ~~April~~January 16, ~~2018~~2019	By:	/s/ Tony Liu
	Name:	Tony Liu
		Principal Executive Officer

Date: ~~April~~January 16, ~~2018~~2019	By:	/s/ Chan Cheung
	Name:	Chan Cheung
		Principal Accounting Officer